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Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is a chronic relentless neurodegenerative 
disorder also known as Lou Gehrig’s disease or Charcot’s sclerosis. It is the most 
common motor neuron disorder of the adult life, with an average onset at the age of 
50-60 years. The incidence is uniformly scattered throughout the world and it is 
about 1-2 per 100.000 people, whilst the prevalence is 4-5 per 100.000 individuals. 
Males are slightly more commonly affected than females, with a ratio men to 
women of about 1,6/1. Affected people show the typical signs of both upper and 
lower motor neuron damage, i.e. clonus, hyperreflexia, spasticity, fasciculation, 
progressive muscle weakness, dysphagia. Symptoms progressively worsen till 
death, usually due to respiratory failure, within 1-5 years from the clinical onset 
(Bruijn et al., 2004; Cleveland and Rothstein, 2001; Pasinelli and Brown, 2006; 
Strong, 2003; Valentine et al., 2005). The causes of this phenotype are the selective 
loss of cortical, brainstem and spinal cord motor neurons as well as the Wallerian 
degeneration of the descending axons with neurofilament accumulation. Dying 
neurons are characterized by the presence of protein aggregates including 
ubiquitinated inclusions, neurofilament-rich “hyaline conglomerated inclusions” 
and Bunina bodies, dense and refractile eosinophilic inclusions of lysosomal origin 
and cytoskeletal disorganization (Dal Canto and Gurney, 1995). These processes 
are often accompained by intense astrocytosis and microgliosis (McGeer and 
McGeer, 2002). 
Some motor neurons are unaffected till very late stages of the disease, namely 
neurons of the Onuf’s nucleus, deputed to control bladder evacuation, and those of 
the oculomotor nucleus (Strong et al., 2005). 
Although ALS has been first described by the French physician Jean-Martin 
Charcot in the XIX century (Charcot, 1869), its aetiopathogenesis remains largely 
unknown. In the 90-95% of clinical cases, the disease occurs with no apparent 
genetic linkage (sporadic ALS, sALS), whilst in the remaining 5-10%, the disease 
is inherited (familial ALS, fALS). Importantly, sALS and fALS occurrences are 
indistinguishable in terms of both clinical signs and neuropathology .  
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Genetics of amyotrophic lateral sclerosis 
Familial ALS is generally inherited as an autosomic dominant pathology, although 
a recessive form and an X-linked phenotype have been described. Extensive genetic 
analyses have been performed so far and have allowed the linkage between ALS 
and mutations in different genes and specific genetic loci.  
 
Superoxide dismutase 1 
The major breakthrough in the field was achieved by Rosen et al. (Rosen et al., 
1993), who found that a number of families with fALS harbored mutations in the 
gene coding for the enzyme superoxide dismutase 1 (SOD1). As yet, more than 150 
different ALS-associated point mutations in the sequence of the SOD1 gene, located 
on chromosome 21q22.1, have been described 
(http://alsod.iop.kcl.ac.uk/Als/index.aspx   Fig. 1a) and account for about 20% of 
fALS. SOD1 is an ubiquitously expressed enzyme of 153 amino acids. It is a 
metalloprotein, as it coordinates an atom of copper and one of zinc. The zinc allows 
the proper folding and stabilization of the protein, whilst the copper is necessary for 
its enzymatic activity. SOD1, indeed, acts as a homodimer to detoxify, through a 2-
steps reaction, the superoxide anion produced during the cell metabolism. In 
particular, the catalytic copper is first reduced to Cu+ with oxygen formation and 
then it is oxidized to Cu2+ with the production of hydrogen peroxide (Fig. 1b).  
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Fig.1 Human SOD1 structure and normal catalytic activity  
 
(a) secondary structural representation of human SOD1 showing the locations of 
fALS-associated mutations (left) and a monomer of SOD1 (right) colored to match 
the drawing on the left (from (Selverstone Valentine et al., 2005)). (b) schematic 
representation of the two emi-reactions catalyzed by SOD1 (E = enzyme) 
 
Most of the identified mutations generate amino acid substitution throughout the 
primary and the tertiary structure of the protein, whilst others give rise to truncated 
proteins. Generally, all these mutations confer an autosomal dominant phenotype 
with a 100% of penetrance, with some exceptions. Namely, SOD1-D90A1 is usually 
dominant, although in Scandinavian populations it was reported to be recessive, 
implying that other genes may influence the clinical outcome. Therefore, different 
                                                 
1 Mutations are conventionally expressed referring to the protein sequence, namely 
indicating the corrispondent aminoacid, its position and the aminoacid that substitutes it 
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mutations can give rise to phenotypic variations, such as different age of onset, 
disease progression or main affected district (Andersen, 2006). 
The advent of transgenic mice allowed great advances in the field, including the 
confirmation of a causative relationship between the expression of mutant SOD1 
(mtSOD1) and the disease. Of the more than 100 mutations in humans, 3 (SOD1-
G85R, SOD1-G37R, and SOD1-G93A) have been extensively characterized in 
transgenic mouse models of ALS (Bruijn and Cleveland, 1996; Gurney et al., 1994; 
Ripps et al., 1995) (Wong et al., 1995). In these mice, the mutant human protein is 
ubiquitously expressed (under the control of the human or mouse SOD1 gene 
promoter) at levels equal to or several fold higher than the level of endogenous 
SOD1. Unlike the variable pattern in humans, weakness typically starts in the hind 
limbs between 3 and 12 months of age, depending on both the mutation and the 
level at which mtSOD1 is expressed. Hind limb weakness coincides with increased 
astrogliosis, activation of microglia, and loss of spinal cord motor neurons. Thus, 
pathology in these mice closely mimics many aspects of the human disease.  
This amount of evidence and the fact that turning off mutant human SOD1 
(hSOD1) expression in transgenic mice by small interfering RNAs (siRNAs) 
reversed the pathological phenotype, definitely confirmed a cause-effect 
relationship between mtSOD1 expression and ALS development (Ralph et al., 
2005; Raoul et al., 2005; Saito et al., 2005; Wang et al., 2008; Xia et al., 2006). 
Nevertheless, despite several years of intense research, it is still unclear as to how 
the mutations in the SOD1 gene induce this disease. It was first hypothesized that 
mtSOD1s could lose their physiological activity, but this statement was proven 
untrue by studies performed on both human samples and transgenic animals. 
Indeed, dismutase activity level did not correlate with the age of disease onset or 
with the rapidity of progression in patients (Bowling et al., 1995; Cleveland et al., 
1995). Moreover, transgenic mice expressing different mutant hSOD1s developed 
the pathological phenotype despite normal (Borchelt et al., 1994; Bruijn et al., 
1997b 1995 #33) or even elevated (Gurney et al., 1994 1995 #27) enzymatic 
activity. Finally, genetic ablation of the sod1 gene in transgenic mice neither caused 
motor neuron pathology nor affected the lifespan (Reaume et al., 1996). Therefore, 
mtSOD1 toxicity was later ascribed to a gain of an unknown function, rather than to 
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the loss of its enzymatic activity. The different pathogenetic hypotheses related to 
this issue will be discussed in details in the next sections. 
 
Alsin 
A juvenile form of ALS has also been described (Ben Amida et al., 1990). In these 
cases the disease is inherited as recessive trait and it is characterized by slow 
progression and a predominant upper motor neuron phenotype. In 2001, two groups 
independently identified the gene alsin in the locus 2q33 (ALS2) as the mutation site 
responsible for this type of pathology (Hadano et al., 2001; Yang et al., 2001). 
Since then, a total of 19 independent ALS2 mutations from 17 families have been 
reported (Hadano et al., 2001; Hadano et al., 2007; Herzfeld et al., 2009; Mintchev 
et al., 2009; Shirakawa et al., 2009; Sztriha et al., 2008; Verschuuren-Bemelmans et 
al., 2008; Yang et al., 2001). These mutations are predicted to result in either 
premature termination of translation or substitution of an evolutionarily conserved 
amino acid in alsin, the ALS2-coded protein, leading to loss of its function. Alsin is 
a 184 KDa protein ubiquitously expressed, particularly in neurons, and localized to 
the cytoplasmic face of the endosomal membranes (Yamanaka et al., 2003). It 
contains three putative guanine nucleotide exchange factor (GEF) domains, 
involving Ras, Rab and Ran motifs. GTPases of the Ras subfamily regulate cellular 
signalling that couples extracellular signals to intracellular responses regulating 
vesicle transport and microtubule assembly. Although its function is not fully 
understood, it is known to act as an exchange factor for Rab5a in vitro (Otomo et 
al., 2003), which regulates endosomal trafficking and Rac1 activiy (Kanekura et al., 
2004) and is involved in macropinocytosis-associated endosome trafficking and 
fusion (Kunita et al., 2007; Otomo et al., 2008) and neurite outgrowth (Jacquier et 
al., 2009; Jacquier et al., 2006; Otomo et al., 2008).  
Because affected families displayed frameshift mutations that lead to aberrant 
proteins without detectable functional domains, it was initially postulated that this 
form of ALS might be simply due to the loss of alsin function. To verify this 
hypothesis, different lines of transgenic mice that do not express alsin were 
generated (Cai et al., 2005; Devon et al., 2006; Yamanaka et al., 2006). However, 
mice lacking ALS2 do not recapitulate the complex disease phenotypes, despite 
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subclinical levels of motor dysfunction and axonal degeneration in aged animals 
(Cai et al., 2008; Hadano et al., 2006; Hadano et al., 2007). Thus, potentially 
important clinical implications raised from these observations, but the physiological 
functions of alsin and the molecular mechanisms underlying motor dysfunction 
resulting from ALS2 deficiency remain to be clarified. 
 
Dynactin 
A variety of additional genes linked to other subtypes of ALS have been recently 
identified (reviewed in (Shaw, 2005)). In particular, a mutation in the gene 
encoding a subunit of dynactin was described in a family showing a phenotype 
characterized by early adulthood onset with respiratory difficulties (Puls et al., 
2003). This finding corroborated previous studies in mice that develop motor 
neuron degeneration caused by disruption of normal dynactin/dynein function 
(LaMonte et al., 2002 2003 #247). As these proteins are deputed to the retrograde 
axonal transport of vesicle and organelles, this evidence highlighted the importance 
of this cellular function for proper motor neuron viability. 
 
Senataxin 
Missense mutations in SETX cause an autosomal dominant, juvenile onset motor 
neuron disease with distal muscle weakness and atrophy, normal sensation, 
pyramidal signs and a normal life-span. SETX encodes a 303 kDa DNA/RNA 
helicase domain with homology to human RENT1 and IGHMBP2 — two genes 
that encode proteins involved in RNA processing (Chen et al., 2004; Chen et al., 
2006b). Altered RNA processing is implicated in two other inherited motor neuron 
diseases — i.e. spinal muscular atrophy (with mutations in the survival motor 
neuron gene) or a severe, infantile, distal spinal muscular atrophy with prominent 
respiratory dysfunction (SMARD; spinal muscular atrophy with respiratory distress, 
with mutations in IGHMBP2). 
 
VAMP-associated protein B 
The gene VAPB has six exons that encode a ubiquitously expressed 27.2 kDa 
homodimer, which belongs to a family of intracellular vesicle-
Introduction 
 7
associated/membrane-bound proteins that are presumed to regulate vesicle 
transport. 
Defects in this gene cause adult-onset, autosomal dominant ALS and atypical ALS 
(slowly progressive with tremors) but not frontotemporal dementia (for an example, 
see (Skibinski et al., 2005)).  
 
TDP-43 
TDP-43 (TAR DNA-binding Protein) is a 43 KDa protein encoded by the TARDBP 
gene located on chromosome 1 (Arai et al., 2006; Neumann et al., 2006). In normal 
conditions, TDP-43 is a nuclear protein which regulates transcription and RNA 
splicing, and participates in mRNA transport and stability (Moisse et al., 2009b; 
Strong et al., 2007) (Buratti and Baralle, 2008). Various missense mutations of 
TDP-43 gene have been identified (Gitcho et al., 2008; Sreedharan et al., 2008); 
(Kuhnlein et al., 2008; Rutherford et al., 2008); (Baumer et al., 2009; Corrado et al., 
2008; Daoud et al., 2009; Del Bo et al., 2009; Kamada et al., 2009; Yokoseki et al., 
2008); (Benajiba et al., 2009; Kirby et al., 2010; Xiong et al., 2010). Mutant TDP-
43 could be involved in 3% familial ALS and 2.9% sporadic ALS (Sreedharan et 
al., 2008); (Lagier-Tourenne and Cleveland, 2009) (Daoud et al., 2009). The 
dysfunction of TDP-43 resulting from the mutation, which induced apoptosis and 
mislocalization of TDP-43, and caused shorter motor neuronal axons could also 
play an essential role in the pathogenesis of ALS (Sreedharan et al., 2008; Winton 
et al., 2008; Johnson et al., 2008; Kabashi et al., 2010; Chen-Plotkin et al., 2010). 
Many studies have shown that TDP-43 in tissues taken from cases of FTLD-TDP or 
ALS is often hyperphosphorylated, cleaved, ubiquitinated, mislocalized, and poorly 
soluble (Arai et al., 2006; Chen-Plotkin et al., 2010; Neumann et al., 2006) and 
TDP-43 aggregates are present in the cytosol and the nucleus of neuronal and glial 
cells of ALS patients, with the striking exception of patients with familial ALS 
caused by SOD1 mutations (Lagier-Tourenne and Cleveland, 2009). It is still not 
clear if these aggregates are a causative event in the pathogenesis of ALS or if they 
are a consequence of the pathological process but these features suggest various 
loss of function and gain of toxic functions for TDP-43 with a possible role in 
disease pathogenesis (Chen-Plotkin et al., 2010). In addition, upregulation of TDP-
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43 expression with prominent cytosolic localization in motor neurons injured by 
degenerative processes such as ALS could represent an appropriate response to 
neuronal injury (Moisse et al., 2009a). The observation that the majority of 
inclusion-bearing cells in patients display nuclei devoid of TDP-43 led to the 
hypothesis that some of the deleterious effects of abnormal TDP-43 metabolism 
may reflect a loss of TDP-43 nuclear function (Igaz et al., 2008).  
 
FUS/TLS 
The identification of TDP-43 mutations in ALS patients was rapidly followed by 
the association of another RNA/DNA-binding protein, named FUS/TLS (fused in 
sarcoma/translocated in liposarcoma) with this disorder (Kwiatkowski et al., 2009; 
(Vance et al., 2009). Thirty mutations have now been reported in about 4% of 
familial ALS and in rare sporadic patients with no apparent familial history. The 
inheritance pattern is dominant except for one recessive mutation (H517Q) found in 
a family of Cape Verdean origin (Kwiatkowski et al., 2009). Most are missense 
mutations with a few exceptions. 
Similar to TDP-43, FUS is ubiquitously expressed and it is mainly localized into the 
nucleus of both neuronal and glial cells (Aman et al., 1996; Andersson et al., 2008). 
However, post-mortem analysis of brain and spinal cord from patients carrying 
FUS/TLS mutations identified abnormal FUS/TLS cytoplasmic inclusions in 
neurons and glial cells (Belzil et al., 2009; Corrado et al., 2010; Kwiatkowski et al., 
2009; Tateishi et al., 2009; Vance et al., 2009). These inclusions were reported to 
be immunoreactive for FUS/TLS as well as for other proteins, including 
GRP78/BiP, p62 and ubiquitin, but strikingly not for TDP-43, implying that 
neurodegenerative processes driven by FUS/TLS mutations are independent of 
TDP-43 mislocalization (Vance et al., 2009; (Suzuki et al., 2010; Tateishi et al., 
2009).  
The mechanisms that determine the FUS subcellular localization are not fully 
understood. Since the molecular weight of human FUS protein is 53,426 daltons 
and the cutoff for passive diffusion through the nuclear pore complex is estimated 
to vary between 40 and 60 kDa (Gerace, 1995; Peters, 2009; Rout et al., 2003), it is 
theoretically possible but likely difficult for FUS to migrate across the nuclear pore 
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complex by this route. In keeping, there is no classic nuclear localization sequence 
(NLS) reported or predicted in FUS and bioinformatic attempts revealed no 
classically predictable NLS (eg, PredictNLS server at 
cubic.bioc.columbia.edu/services/predictNLS; (Cokol et al., 2000)). However, it has 
been suggested that the C-terminus of FUS could work as NLS (Gal et al., 2010). In 
this context, it is interesting to note that most of the FUS mutations identified to 
date are clustered in the C-terminus of the protein (Kwiatkowski et al., 2009; Vance 
et al., 2009). 
 
Similarities between the pathologies caused by TDP-43 and FUS mutants have been 
identified. Although the two proteins are not closely related, they share similar 
sequence elements, such as the RNA recognition motif (Ou et al.) domain and 
glycine-rich regions, which are common to RNA/DNA binding proteins (Lagier-
Tourenne and Cleveland, 2009). Furthermore, similar to FUS, TDP-43 has been 
reported to play roles in RNA transcription, splicing, and transport (Buratti and 
Baralle, 2008; Volkening et al., 2009). Both proteins are normally mostly nuclear in 
neurons, and their molecular features in ALS encompass their mislocalization to the 
cytoplasm and the formation of protein inclusions (Arai et al., 2006; Kwiatkowski 
et al., 2009; Kwong et al., 2007; Neumann et al., 2006; Sreedharan et al., 2008; 
Vance et al., 2009).  
 
In addition to the genes described above, several potential risk factors for ALS have 
also been identified. Among these, there are polymorphisms of the neurofilament 
heavy chain (NF-H), the ciliary neurotrophic factor (CNTF) and the vascular 
endothelial growth factor (VEGF) (Bruijn et al., 2004). Furthermore, Amyotrophic 
lateral sclerosis has also been associated to a mutation of the glial glutammate 
transporter EAAT2 (Trotti et al., 2001).  
 
Pathogenesis of ALS 
The discovery of mutations in the SOD1 gene allowed the development of several 
mouse models of ALS. These transgenic animals represent the most useful tool to 
study the mechanisms underlying the pathology outcome. Since the clinical 
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presentation of fALS and sALS is indistinguishable, it is possible to hypothesize 
that, whatever is the triggering cause, the pathological process passes through 
common pathways. Thus, the disease mechanisms extrapolated from studies on 
mutant SOD1 transgenic mice may be of interest also for the sporadic form of the 
disease. Among the recognized pathogenetic hypotheses, there are oxidative stress, 
excitotoxicity, protein aggregates, mitochondrial damage, cytoskeletal 
disorganization, trophic factor deficiency, neuroinflammation and the detrimental 
actions of non neuronal cells. 
 
Oxidative stress 
Despite intense experimental efforts, it is still unclear as to how mtSOD1 can cause 
ALS. As described in the genetics section, SOD1 is an antioxidant enzyme whose 
toxicity seems to be due to the gain of a deleterious function.  
On these bases, it was first hypothesized that the mutant protein could display 
anomalous activity, namely handling aberrant substrate, such as hydrogen peroxide 
(Wiedau-Pazos et al., 1996), the normal end-product of its catalytic activity. In this 
study, it was proposed that, in vitro, H2O2 could be transformed by mtSOD1 into 
the highly reactive hydroxyl radical, triggering a peroxidation cascade. However, 
the evidence of this phenomenon in vivo was not exhaustive because signs of 
peroxidation were found in hSOD1-G93A mice (Andrus et al., 1998; Hall et al., 
1998a), but not in other models (Bruijn et al., 1997a). 
Another proposed substrate for mtSOD1 was peroxynitrite, which is the end-
product of the reaction between superoxide and nitric oxide (NO). Initially, it was 
suggested that the spontaneously formed peroxynitrite could be used by the mutant 
enzymes to cause protein nitration (Beckman et al., 1993). However, a more 
articulated hypothesis was later postulated, starting from the observation that some 
mtSOD1s bind zinc ions less efficiently (Crow et al., 1997) and that zinc depleted 
SOD1s induce NO-dependent cell death in cultured primary neurons (Estevez et al., 
1999). It was therefore proposed that zinc deficiency, in the presence of bound 
copper, facilitates the reversal of the usual reaction, namely the conversion of 
oxygen into superoxide (Estevez et al., 1999). It is to mention that also the 
peroxynitrite-hypothesis was weakened by in vivo studies, mainly because the 
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pharmacological reduction of NO levels pharmacologically (Upton-Rice et al., 
1999) or the disruption of the n-nos (Facchinetti et al., 1999) or i-nos genes (Son et 
al., 2001) did not delay disease onset or improve survival. 
All the issues addressing the oxidative stress hypothesis have in common the 
requirement for the catalytic activity of SOD1, which relies on the presence of the 
copper ion in the active site. Therefore, it was speculated that disrupting copper 
loading in vivo could improve the pathological phenotype. To address this issue, 
two transgenic mouse models were generated. The first one was based on a 
previous finding, namely the discovery that in yeast SOD1 requires a specific 
chaperone, the copper chaperone for SOD1 (CCS) (Culotta et al., 1997), to load 
copper. Transgenic mice devoid of CCS were therefore generated and cross-bred 
with different transgenic mouse models of ALS (Subramaniam et al., 2002). 
Unfortunately, disease onset and progression was not modified, even if copper 
loading into SOD1 motor neurons was greatly reduced. The other model consisted 
in transgenic mice harboring a mtSOD1 in which all the histidines necessary to 
coordinate copper were replaced (Wang et al., 2003), but also in this case, the 
animals displayed an ALS-like phenotype. 
A microarray study of motor neuronal cells expressing mutant SOD1 reported 
down-regulation of genes involved in the antioxidant response, including the 
transcription factor Nrf2 (nuclear erythroid 2-related factor 2), several members of 
the glutathione S-transferase family, and two peroxiredoxins (Kirby et al., 2005). 
Reduced Nrf2 messenger RNA (mRNA) and protein expression has more recently 
been reported in spinal cord neurons from ALS patients (Sarlette et al., 2008). 
Activation of Nrf2 leads to its translocation into the nucleus, where it interacts with 
the antioxidant-response element (ARE) to drive the expression of antioxidant 
enzymes (Nguyen et al., 2009); furthermore Nrf2 regulates also its own expression 
through an auto-regulatory loop (Kwak et al., 2002). Although it is currently 
unclear how Nrf2 expression comes to be down-regulated in ALS patients, it should 
be noted that cellular Nrf2 levels declined by over 50% in old rats (24 months) 
relative to young rats (3 months) (Suh et al., 2004). Given that increased age is one 
of the major known risk factors for developing ALS, it seems conceivable that the 
mechanism(s) involved in the age-related down-regulation of Nrf2 may also 
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contribute to the down-regulation observed in ALS patients. Down-regulation of 
Nrf2 expression in ALS may reduce the ability of the cells to remove ROS 
generated through normal cellular metabolism, resulting in a gradual increase in 
oxidative stress over time. 
 
Excitotoxicity 
Glutamate is the major excitatory amino-acid of the central nervous system (CNS). 
While normal glutamate levels mediate physiological neurotransmission, elevated 
concentrations trigger excitotoxicity, a form of neuronal cell death with its own 
features (reviewed in (Arundine and Tymianski, 2003)). In order to prevent this 
deleterious event, glutamate is normally cleared from the synaptic cleft by specific 
transporters, named EAAT1-5 (reviewed in (Danbolt, 2001)), expressed both on 
neurons and on the surrounding glia.  
Several findings suggest a role for excitotoxicity in the pathogenesis of ALS, since 
studies on patients showed increased glutamate levels in cerebrospinal fluid (CSF) 
(Fiszman et al., 2010). This extracellular accumulation of neurotransmitter was 
proposed to be due to a reduced uptake of the amino acid and, therefore, expression 
and activity levels of glutamate transporters were then investigated.  
Particular attention was focused on the astrocyte specific transporter EAAT2, which 
is responsible for about 90% of the extracellular glutamate removal (Miller et al., 
1996, Tanaka, 1997 #49). Its presence is necessary for neuronal survival, as 
reducing EAAT2 expression levels by antisense nucleotide was described to cause 
neuronal demise (Rothstein et al., 1996). Interestingly, the selective loss of EAAT2 
was reported in ALS patients (Rothstein et al., 1995) as well as in both transgenic 
mouse (Bendotti et al., 2001b; Bruijn et al., 1997b) or rat (Howland et al., 2002) 
models of the disease. Various mechanisms for EAAT2 loss have been proposed, 
from mRNA aberrant splicing (Lin et al., 1998), that was observed also in 
Alzheimer patients, to the recently proposed selective cleavage of this transporter 
by caspase-3 (Boston-Howes et al., 2006) and subsequent sumoylation of the 
EAAT2 fragment which accumulates into the nucleus of spinal cord astrocytes 
(Gibb et al., 2007). If this event is relevant to the pathogenetic cascade, increasing 
the expression levels of EAAT2 should improve the clinical course of the disease. 
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In keeping with this hypothesis, the overexpression of EAAT2 in hSOD1-G93A 
mice delayed the grip strength decline, even though paralysis onset and life span 
were not affected (Guo et al., 2003). Moreover, a wide screen of the US Food and 
Drug Administration (FDA)-approved drugs has been recently performed to 
identify clinically available molecules able to increase EAAT2 expression levels 
(Rothstein et al., 2005). Surprisingly, beta-lactam antibiotics have proven useful to 
reach this aim and their efficacy has been therefore tested in vivo. Ceftriaxone has 
been delivered to hSOD1-G93A transgenic mice and the treated mice displayed 
delayed paralysis onset and prolonged life-span, thus demonstrating that a 
pharmacological therapy based on increasing EAAT2 function may be 
neuroprotective (Rothstein et al., 2005). As antibiotics are clinically tested drugs, a 
clinical trial to evaluate the efficacy of ceftriaxone is currently ongoing.  
A decrease in the transporter expression level is not the only possible cause of its 
functional impairment: mutations or post-transcriptional modifications may also 
alter its properties. According to this hypothesis, a mutation in the EAAT2 gene, 
leading to reduced activity, was recently identified in a patient with sporadic ALS 
(Trotti et al., 2001). Moreover, EAAT2 was demonstrated to be very sensitive to the 
oxidative stress generated by two endogenous oxidants implicated in ALS 
pathogenesis: H2O2 (Volterra et al., 1994) and peroxynitrite (Trotti et al., 1996). 
Taken together, these findings provide evidence that the oxidative stress and the 
excitotoxic hypothesis are interrelated and may be considered as two aspects of a 
unique pathogenic pathway.  
It is well known that excitotoxicity can be triggered not only by increased 
extracellular glutamate concentrations, but also by alterations of the glutamate 
receptors that lead to an improved sensibility to the toxic action of the 
neurotransmitter. This could be the case of motor neurons in ALS. Indeed, these 
cells normally display a particular vulnerability to glutamate especially following 
the activation of AMPA receptors (Terro et al., 1998), a feature that may be further 
increased in ALS. In cell culture studies, mtSOD1 can increase glutamate toxicity 
acting by altering AMPA receptor subunit composition (Roy et al., 1998). 
Normally, AMPA receptors are Ca2+-impermeable, as they display the properly 
edited GluR2 subunit, but may become Ca2+-permeant upon defective editing of the 
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G/R site. Therefore the proper editing of GluR2 and the subunit composition are 
critic to prevent excessive Ca2+ intake and toxicity. In agreement with this proposal, 
samples from ALS patients displayed alteration in GluR2 editing especially in 
motor neurons (Kawahara et al., 2004; Kwak and Kawahara, 2005; Takuma et al., 
1999). Furthermore an increase in GluR3 AMPA subunit expression in animal 
models of ALS has been demonstrated (Spalloni et al., 2004; Sun et al., 2006) 
leading to a reduction of the ratio between GluR2 and GluR3 which is likely to be 
harmful to neurons. Consistently, administrating GluR3 antisense protein nucleic 
acid (Rembach et al., 2004) or overexpressing GluR2 (Tateno et al., 2004) 
prolonged mice survival. Conversely, mice lacking the GluR2 subunit showed a 
reduced survival (Van Damme et al., 2005).  
Finally, it is worth to cite that the only drug approved for ALS treatment is riluzole, 
which is an antiglutamatergic drug. This compound was able to prolong survival 
both in transgenic mice (Gurney et al., 1998) and in patients (Bensimon et al., 1994; 
Lacomblez et al., 1996; Miller et al., 1996). 
 
Protein aggregates 
The presence of abnormal protein aggregates is a common feature of different 
neurodegenerative disorders, namely prion diseases, Alzheimer’s disease, 
Parkinson’s disease, Huntington’s chorea and even ALS. Their significance is still 
debated, as they could be either detrimental or beneficial (Soto, 2003). In ALS, the 
presence of different intracellular cytoplasmic inclusions is a typical hallmark of 
dying motor neurons (reviewed in (Strong et al., 2005)). Interestingly, in transgenic 
animals, hSOD1 aggregates were detected in both motor neurons and astrocytes 
(Dal Canto and Gurney, 1995) (Bruijn et al., 1998; Dal Canto and Gurney, 1995; 
Furukawa and O'Halloran, 2006; Gurney, 1994; Miller et al., 2004; Pasinelli et al., 
2000). Furthermore, SOD1 aggregates were found also in ALS patients (Shibata et 
al., 1996; Shibata et al., 1994) that lack mutations in this enzyme (Forsberg et al., 
2010). Mutant hSOD1 aggregates have been found in the brain on both the matrix 
and the cytoplasmic face of mitochondria (Cleveland and Liu, 2000; Manfredi and 
Xu, 2005; Pasinelli et al., 2004; Vande Velde et al., 2008b; Vijayvergiya et al., 
2005). Since protein aggregates were detected before the onset of symptoms (Bruijn 
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et al., 1998) and selectively in ALS tissues (Durham et al., 1997), it is likely that 
protein misfolding could be part of mtSOD1 toxicity. Many hypotheses were 
formulated to explain this issue including the one suggesting that aggregates may 
sequester other proteins (Watanabe et al., 2001) or alter the proper function of 
cellular organelles, such as mitochondria (see below). Among the proteins detected 
in the aggregates, there were also ubiquitin and chaperone proteins. The former is 
normally responsible for proper intracellular proteolysis (Ciechanover, 2005) and 
its sequestration may lead to a reduced proteasome activity (Allen et al., 2003), 
which in turn alters the physiological protein turnover. The latter are a group of 
proteins that promote the correct folding of protein (Bukau et al., 2006). Some of 
them, the heat-shock protein 40 and 70 (HSP40 and HSP70), form insoluble 
aggregates with mtSOD1. Interestingly, reduction in the availability of HSP70 
seems to mediate part of the toxicity induced by mtSOD1, as overexpression of the 
chaperone protein can ameliorate neuronal sufferance (Bruening et al., 1999). 
Furthermore, hSOD1-G93A transgenic mice treated with arimoclamol, a HSP70 
inducer, displayed a prolonged life span (Kieran et al., 2004). 
A recent work by Poletti and colleagues demonstrated that HspB8 is overexpressed 
in hSOD1-G93A NSC34 cells and in motor neurons of hSOD1-G93A mice. Their 
findings indicate that HspB8 increases mutant SOD1 solubility and clearance by 
activating the autophagic removal of the misfolded mutant SOD1 in NSC-34 cells.  
 
Mitochondrial damage   
Since mitochondrial morphological abnormalities were initially described in 
proximal axons as well as in the ventral horns of sALS patients (Hirano et al., 
1984), several studies have been focused on this issue (reviewed in (Hervias et al., 
2006)). Data obtained from autoptic samples did not provide conclusive evidence 
whether such alterations are causative or mere by-products of the degenerative 
mechanism. Therefore, further investigations to solve this question were performed 
both in vitro and in transgenic mouse models of fALS. 
Mitochondrial depolarization, an indicator of respiratory chain dysfunction, and 
alterations in calcium homeostasis were observed in both neuroblastoma cells 
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transfected with the mtSOD1 (Carri et al., 1997) and primary neurons from hSOD1-
G93A mice (Menzies et al., 2002). 
Degenerating mitochondria were described in two different transgenic lines, namely 
those expressing either hSOD1-G93A (Dal Canto and Gurney, 1995) or hSOD1-
G37R (Wong et al., 1995). Moreover, in hSOD1-G93A mice, the number of 
vacuolated mitochondria increased dramatically at the onset of the disease, when 
neuronal loss was still limited, suggesting that mitochondrial alterations may be a 
triggering event in the pathogenesis of fALS (Kong and Xu, 1998). Ultrastructural 
studies showed that vacuoles may derive from expansion of the intermembrane 
space (Bendotti et al., 2001a), with subsequent collapse and degradation of the 
inner membrane (Higgins et al., 2003; Xu et al., 2004).  
Based on all these observations, the connection between mtSOD1 and degenerating 
mitochondria was investigated. Initially, the localization of both mutant and wild 
type SOD1 was determined in the mitochondria of mouse brain and spinal cord 
(Mattiazzi et al., 2002), particularly in motor neurons (Higgins et al., 2002; Jaarsma 
et al., 2001). Abnormal clustering of mitochondria was recently reported in motor 
axons in mutant SOD1 transgenic mice (Sotelo-Silveira et al., 2009). However, the 
fine ultrastructural SOD1 localization within the mitochondria is still debated and 
probably it may be affected by the techniques utilized in the experimental plan. 
Mattiazzi and colleagues first proposed that SOD1 concentrates in the 
intermembrane space of mitochondria (Mattiazzi et al., 2002), but other groups 
demonstrated the association of the mutant enzyme with the cytoplasmic face of the 
outer membrane. This may be mediated by the interaction with integral membrane 
components (Liu et al., 2004), such as the anti-apoptotic protein Bcl-2 (Pasinelli et 
al., 2004) or the cytoplasmic exposed face of voltage-dependent anion channel 1 
(VDAC1) (Israelson et al., 2010). Also Vande Velde and colleagues recently 
demonstrated a strong binding of misfolded mtSOD1 to the cytoplasmic face of 
mitochondria (Vande Velde et al., 2008a). 
Copper chaperone for SOD1 (CCS) is also partially localized in mitochondria 
(Sturtz et al., 2001) and assists in the entry and retention of SOD1 in mitochondria 
(Field et al., 2003). Increased localization of mutant SOD1 in mitochondria by CCS 
overexpression in the CCS/hSOD1-G93A double transgenic mice caused early 
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mitochondrial pathology and accelerated disease course (Son et al., 2007). The 
presence of SOD1 aggregates was detected also in the brain mitochondrial matrix 
(Vijayvergiya et al., 2005). Although mtSOD1 presence was demonstrated in other 
subcellular compartments in mice (Kikuchi et al., 2006), only the mitochondrial 
localization appeared to be sufficient to trigger cell death in neuroblastoma cells 
expressing mtSOD1 targeted to different organelles (Takeuchi et al., 2002). 
The mechanisms underlying these abnormalities are still object of intense studies, 
because an exhaustive demonstration of the cause-effect relationship between 
mtSOD1, mitochondrial dysfunction and neurotoxicity has not yet been provided. 
However, a recent finding seems to corroborate the hypothesis that the 
mitochondrial localization might mediate neurotoxicity. Indeed, it was 
demonstrated in cell culture that dorfin overexpression is useful to reverse mtSOD1 
toxicity (Niwa et al., 2002), by reducing its mitochondrial localization (Takeuchi et 
al., 2004). Dorfin is a RING finger-type E3 ubiquitin ligase and it is localized in 
inclusion bodies in both sALS and fALS. It seems that dorfin binds ubiquitin to 
mtSOD1, thereby enhancing its clearence (Niwa et al., 2002).  
Morphological abnormalities are not the only reported mitochondrial alterations, 
but also different functional impairments were described. The role of mitochondria 
within the cell is twofold: they provide energy with the mitochondrial electron 
transport chain and they simultaneously compartmentalize several molecules that 
may trigger apoptosis if released in the cytosol. As both of these functions seem to 
be affected in ALS, the former will be discussed below, whilst the latter in the next 
section. 
A reduction in enzymatic activity of the respiratory chain complexes (Jung et al., 
2002; Mattiazzi et al., 2002 2005 #76) and a decreased capacity to consume oxygen 
and to synthesize ATP (Mattiazzi et al., 2002) were first demonstrated. 
Interestingly, the bioenergetic failure was then correlated to a reduction in 
mitochondrial calcium loading capacity (Damiano et al., 2006), thereby providing a 
link between alterations of these organelles and excitotoxicity (see above). Some of 
these effects (Damiano et al., 2006; Kirkinezos et al., 2005) were detected before 
the clinical onset of the disease. Elevated calcium can induce reactive oxygen 
species and oxidative stress in primary motor neurons isolated from hSOD1-G93A 
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mice (Kruman et al., 1999). Alternatively, calcium-mediated glutamate 
excitotoxicity might contribute to the mutant SOD1 toxicity in motor neurons.  
Also the axonal transport of mitochondria is impaired in ALS; recent studies 
showed that both the anterograde and retrograde transport of mitochondria were 
altered by mtSOD1 in NSC-34 cells expressing mitochondria-targeted SOD1. In 
addition, mtSOD1 also caused mitochondrial fragmentation and impaired 
mitochondrial dynamics (Magrane et al., 2009; Magrane and Manfredi, 2009). 
The mechanisms by which mtSOD1 disrupts axonal transport of mitochondria are 
not completely understood but several possible scenarios can be hypothesized. 
MtSOD1 can cause a partial loss of mitochondrial membrane potential and thus can 
change axonal transport of mitochondria (Miller and Sheetz, 2004); the elevated 
local calcium concentration induced by decreased mitochondrial buffering 
capability can promote detachment of kinesin heavy chain from microtubule 
(Chang et al., 2006; Wang and Schwarz, 2009; Yi et al., 2004). Furthermore, the 
activated kinases can phosphorylate kinesin subunits and affect anterograde 
transport (De Vos et al., 2000; Morfini et al., 2007; Morfini et al., 2009; Pigino et 
al., 2009; Shibata et al., 2008). Alternatively, activated MAP kinase can also 
phosphorylate neurofilaments and lead to their accumulation in axons (Ackerley et 
al., 2004; Tortarolo et al., 2003). Finally the aberrant interaction between mtSOD1 
and the dineyn-dynactin complex could also disrupt retrograde transport of 
mitochondria (Strom et al., 2008; Zhang et al., 2007). The axonal tranport of 
mitochondria was shown to be impaired in either the anterograde direction (De Vos 
et al., 2007) or in both anterograde and retrograde directions (Magrane et al., 2009). 
Therapeutics targeting mitochondrial functions were delivered to SOD1 transgenic 
mice. In particular, creatine, which improves the metabolic functions of the 
mitochondria, ameliorated the pathological phenotype, increasing the motor 
function (Klivenyi et al., 1999). Unfortunately, different clinical trials (Drory and 
Gross, 2002; Groeneveld et al., 2003; Shefner et al., 2004) failed to demonstrate 
any therapeutic effect of this drug on clinical course of human cases. 
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Cytoskeletal disorganization 
The most abundant structural proteins in several types of motor neurons are 
neurofilaments, which are neuron-specific intermediate filaments appointed to the 
maintenance of the cell shape and axon diameter. The individual proteins are 
classified on the basis of their molecular mass into high- (NF-H), medium- (NF-M) 
and low- (NF-L) molecular weight neurofilaments. These subunits are assembled in 
the cell body and then transported down the axon by slow axonal transport with 
extensive phosphorylation during movement (Strong et al., 2005). 
Several findings led to hypothesis that damage to neurofilaments might be involved 
in the pathogenesis of ALS. First, it was observed that neuronal loss affects 
especially the largest caliber and neurofilament-rich motor neurons, in both patients 
(Kawamura et al., 1981) and in transgenic mice (Bruijn et al., 1997b). Moreover, 
neurofilament accumulation in motor neuronal cell body is a hallmark of ALS 
pathology (Hirano et al., 1984). Finally, mutations in NF-H gene was recognized in 
both sALS and fALS patients (Al-Chalabi et al., 1999).  
To further investigate the role of neurofilaments in the degenerative process, several 
transgenic mice harboring alterations in the filament subunits (reviewed in (Strong 
et al., 2005)) were generated. In some of these models, neurofilament 
overexpression was sufficient to cause axonopathy and selective motor neurons 
degeneration. Therefore, it was proposed that neurofilament subunit deletion in 
ALS models transgenic mice should be neuroprotective. According to this, 
eliminating NF-L in SOD1 transgenic mice significantly extended their lifespan 
(Williamson et al., 1998). Surprisingly, a positive effect on survival was achieved 
also by overexpressing NF-L and NF-H (Kong and Xu, 2000) or NF-H alone 
(Couillard-Despres et al., 1998). This apparent contradiction was explained by 
proponing a different role for the diverse subunits. NF-H was considered important 
to buffer toxic events in the perykarya and therefore its increase could afford further 
protection. On the contrary, NF-L slowed the slow axonal transport that is affected 
early in ALS (Williamson and Cleveland, 1999) and, consequently, its reduction 
may counteract this impairment. 
Another intermediate filament that seems to be involved in ALS pathogenesis is 
peripherin, since it was detected in neurofilament aggregates in motor neurons of 
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ALS patients (Corbo and Hays, 1992). This protein is encoded by a single gene and 
possesses three splice variants, named on the basis of their molecular weight as 
peripherin 56-58-61. Both peripherin 58 overexpression and peripherin 61 
expression seem to be toxic to motor neurons (Robertson et al., 2003). 
In a recent study, a novel human peripherin transcript, resulting in a truncated 
peripherin (Per28), was found upregulated in a case of human ALS, and an 
antibody specific for Per28 stained the filamentous inclusions (Xiao et al., 2008). 
These studies suggest that missplicing of peripherin could lead to disease. 
Additional reports have also implicated mutations in peripherin with ALS (Gros-
Louis et al., 2004; Leung et al., 2004). Several transgenic mice carrying alteration 
in peripherin gene were developed (reviewed in (Strong et al., 2005)) and displayed 
motor impairments. However, crossbreeding these lines with ALS models did not 
affect the course of the disease (Lariviere et al., 2003), suggesting that their actual 
role in ALS pathogenesis deserves further investigations. 
 
Trophic factors deficiency 
Trophic factors, sometimes referred to as neurotrophins, are a family of molecules 
that encourage the survival of the nervous tissue. As certain neuronal populations 
are strictly dependent on trophic factors supply for their survival, it was easily 
hypothesized that motor neurons demise in ALS might be due to their deficiency 
and several of them were investigated. 
Initial attention was focused on ciliary neurotrophic factor (CNTF), as autoptic 
samples from ALS patients displayed a reduced level of this protein (Anand et al., 
1995). Moreover, a mutation in the CNTF gene mutation has been related to a faster 
disease progression in a family carrying also a mutation in the SOD1 gene (Giess et 
al., 2002). Despite these findings indicating an involvement of CNTF in ALS 
pathogenesis, other observations did not corroborate this hypothesis. In particular, 
lack of CNTF gene neither cause motor neuron disease in patients (Takahashi et al., 
1994), nor modifies the clinical course of sALS or fALS carrying the SOD1-D90A 
mutation (Al-Chalabi et al., 2003). 
More attention was given to other trophic factors, such as the glial cell line-derived 
neurotrophic factor (GDNF) and the insulin-like growth factor-1 (IGF-1), as both 
Introduction 
 21
of them support motor neurons in vivo and in vitro (Elliott and Snider, 1996 1996 
#253), perhaps activating different cell survival pathways (Bilak et al., 2001). On 
the basis of these considerations, these factors were delivered to transgenic mouse 
models of ALS in order to test their capability to slow down disease progression. 
Interestingly, hSOD1-G93A mice, which were injected with an adeno-associated 
virus (AAV) expressing IGF-1 (Kaspar et al., 2003), displayed a marked increase in 
their lifespan, even if the treatment was started after the onset of the disease. On the 
contrary, GDNF had only moderate effect. This discrepancy raised questions about 
the mechanism through which IGF-1 might exert its benefic effect and it was 
postulated that the real targets might not be motor neurons, but muscle fibers, as 
demonstrated by the neuroprotective effect of a non-releasable form of IGF-1 
injected directly into skeletal muscle (Dobrowolny et al., 2005). 
Surprisingly, another growth factor seems to be involved in motor neuron 
maintenance, namely the vascular endothelial cell growth factor (VEGF). 
Particular attention was focused on this protein as transgenic mice harboring a 
mutation in the hypoxia-responding element of the VEGF gene unexpectedly 
developed a progressive motor impairment (Oosthuyse et al., 2001). Moreover, 
these animals displayed all the hallmarks of ALS pathology, namely neurofilament 
accumulation in motor neurons, axonal degeneration and progressive muscle 
atrophy (Oosthuyse et al., 2001). Furthermore reduced levels of VEGF have been 
reported in the spinal cord of ALS patients (Brockington et al., 2006). This finding 
led to perform a clinical study to determine whether mutation in VEGF gene may be 
correlated to human cases of ALS. In the European population, sALS was 
associated with three polymorphisms in the promoter region of the gene, leading to 
reduced circulating levels of the protein. However, it is worth mentioning that none 
of these alterations was localized in the hypoxia responding element (Lambrechts et 
al., 2003). Therefore, VEGF may be only a disease modifier, whose effects on ALS 
pathogenesis are strictly dependent on other unknown genetical, enviromental or 
lifestyle factors, as the observed association does not exist in other groups, such as 
an English subpopulation (Lambrechts et al., 2003) or the North Americans (Chen 
et al., 2006a). Nevertheless, the role of VEGF as a neuroprotective tool was 
extensively investigated. Initial in vitro studies demonstrated that this trophic factor 
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is necessary for survival of motor neurons (Van Den Bosch et al., 2004). hSOD1-
G93A mice crossbred with transgenic mice expressing reduced levels of VEGF 
died erlier due to more severe motor neuron degeneration (Lambrechts et al., 2003). 
Conversely hSOD1-G93A crossbred with mice overexpressing VEGF in neurons 
show delayed motor neuron loss, delayed motor impairment, and prolonged 
survival compared with SOD1-G93A single transgenics (Wang et al., 2007). 
hSOD1-G93A transgenic mice injected with a lentivirus encoding VEGF after the 
onset of symptoms showed delayed onset of paralysis, slower disease progression 
and increased lifespan (Azzouz et al., 2004).  
 
Neuroinflammation  
Neuroinflammation is a complex phenomenon characterized by the production of 
inflammatory mediators and by the activation of glial cells (reviewed in (McGeer 
and McGeer, 1995)), namely astrocytes and microglia, which undergo a 
morphological switch in response to CNS injuries. Though it is a shared feature of 
different neurological disorders, such as Alzheimer disease or Parkinson disease, it 
is still an incompletely understood manifestation and it is still debated whether it is 
beneficial or detrimental to the pathological process (Monk and Shaw, 2006).  
Different groups detected increased levels of various inflammatory biochemical 
mediators, namely the inducible enzyme cycloxygenase 2 (COX2) or some 
cytokines, such as interleukin-1β or TNFα in ALS patients as well as in hSOD1-
G93A transgenic mice (Alexianu et al., 2001; Elliott, 2001; Hensley et al., 2002; 
Yoshihara et al., 2002). Interestingly, in this mouse model, cytokine raise was 
reported at a presymptomatic age (Hensley et al., 2002). 
As antiinflammatory compounds are among the most utilized drugs worldwide, 
some of these molecules were delivered to transgenic mice to test their capability to 
slow disease progression. In particular, a COX2 inhibitor, celecoxib, was orally 
administrated to hSOD1-G93A mice, thus obtaining a significant survival 
prolongation (Drachman et al., 2002). Unfortunately, despite this promising result 
in preclinical models, a recent clinical trial failed to demonstrate analogous 
usefulness to treat the human disease (Cudkowicz et al., 2006).  
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As previously mentioned, reactive gliosis is a typical ALS hallmark in both human 
cases (Kawamata et al., 1992) and transgenic animals (Bruijn et al., 1997b; Gurney 
et al., 1994; Wong et al., 1995). Furthermore, in hSOD1-G93A mice, microgliosis 
preceeded the onset of symptoms and progressively worsened in parallel to the 
development of motor function impairment (Alexianu et al., 2001; Hall et al., 
1998b). This last observation gave rise to the possibility that other cell types besides 
motor neurons might be involved in ALS pathogenesis, a hypothesis that will be 
further discussed in the following paragraph. 
 
Detrimental actions of non-neuronal cells 
In the last few years, the contribution of non-neuronal cells to ALS pathogenesis 
has been first recognized, so that ALS is currently considered a non-cell 
autonomous disease. The exact contribution of each cellular population is however 
unidentified, although a potential pathogenetic role for both astrocytes (Barbeito et 
al., 2004) and microglia (Sargsyan et al., 2005) was postulated.  
Physiologically, astrocytes exert several functions ranging from providing trophic 
and metabolic support to neurons, to modulating synaptic activity (reviewed in 
(Volterra and Meldolesi, 2005)). The hypothesis of astrocyte involvement in ALS 
pathogenesis is supported by several observations. As largely discussed in the 
excitotoxicity section, astrocytes regulate extracellular levels of glutamate through 
the action of their specific transporter EAAT2/GLT1, which is down regulated in 
ALS (see above for details). Moreover, mtSOD1 seems to induce directly cell 
damage in astrocytes, as observed in hSOD1-G85R transgenic mice, who display 
ubiquitin-positive mtSOD1 inclusions in these cells earlier than in neurons (Bruijn 
et al., 1997b). 
To establish which is the actual cellular target of mtSOD1 toxicity, different 
transgenic mice lines were generated that express the pathological protein 
selectively in specific cellular populations of the CNS. Astrocyte-specific (Gong et 
al., 2000) mtSOD1 expression was unable to induce the pathological phenotype 
while neuronal-specific mtSOD1 expression was either not pathological 
(Pramatarova et al., 2001) or sufficient to induce the disease (Jaarsma et al., 2008). 
Furthermore, increasing the expression of mtSOD1 selectively in adult neurons did 
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not fasten the course of the disease in hSOD1-G93A mice (Lino et al., 2002). To 
investigate more accurately the contribution of different cell populations to ALS 
pathogenesis, an innovative experimental model was generated and characterized, 
namely chimeric mice harboring a mixture of normal cells and human mtSOD1 
expressing cells (Clement et al., 2003). These mice showed an increased lifespan 
depending on the percentage of wild type cells they possessed. Moreover, mtSOD1-
expressing motor neurons were rescued in the presence of a high percentage of non-
transgenic glial cells. Conversely, signs of cell sufferance in adjacent wild type 
motor neurons accompanied the presence of transgenic non-neuronal cells (Clement 
et al., 2003).  
Taken together, all these observations support the view that mtSOD1 toxicity 
implies the contribution of different cell types in ALS, although they do not provide 
detailed mechanistic insights, which were explored with in vitro studies. The first 
question was to determine if mtSOD1 might induce in non-neuronal cells sufficient 
alterations to trigger motor neuron sufferance. Initially, it was demonstrated that 
mtSOD1-expressing neurons might activate glial cells (Cassina et al., 2005; Ferri et 
al., 2004; Urushitani et al., 2006), which in turn may trigger motor neuron demise 
(Cassina et al., 2002; Pehar et al., 2004). In particular, activated microglia cells 
seems to be particularly detrimental to motor neurons, as they may induce neuronal 
demise through neurite beading by inhibition of mitochondrial respiration and 
axonal fast transport (Takeuchi et al., 2005), well described features in ALS 
histopathology. 
To investigate more sharply the contribution of microglia in vivo, transgenic mice 
carrying a deletable mtSOD1 gene were generated (Boillee et al., 2006). In 
particular, animals harboring the hSOD1-G37R sequence flanked by a pair LoxP 
sequences (LoxSOD1-G37R), which allowed recognition and regulated deletion by 
the Cre recombinase, were produced. These mice, who developed fatal progressive 
ALS-like phenotype, were then cross-breeded with mice expressing Cre 
recombinase under the control of either a neuron- or microglial-specific promoter, 
in order to shut down the expression of the toxic protein selectively in these cell 
populations. The effects on the pathological course resulted different. In particular, 
reduced mtSOD1 levels in motor neurons delayed disease onset without affecting 
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disease progression at later stages, whilst diminishing the mutant SOD1 expression 
in microglia prolonged survival by slowing the rate of motor neurons impairment 
(Boillee et al., 2006). The therapeutic utility of reducing microglial activation was 
also tested with a pharmacological approach. In particular, transgenic mice were 
treated with the antibiotic minocycline (Kriz et al., 2002; Van Den Bosch et al., 
2002; Zhu et al., 2002), a tetracycline derivative able to switch off microglial 
activation (Yrjanheikki et al., 1999). Clinical trials to validate the therapeutic 
efficacy of this molecule are currently underway. Taken together with the studies 
presented in the previous section, these results suggest that microglia and the 
inflammatory process may influence the course of the disease, rather than being a 
cause (McGeer and McGeer, 2002; Monk and Shaw, 2006). In keeping with this 
point of view, transgenic mice harboring the hSOD1-G37R gene under the control 
of the prion protein promoter (PrP:hSOD1-G37R) were generated (Wang et al., 
2005). The use of this specific promoter drives high expression levels of mtSOD1 
in neurons, astrocytes and muscles, but not in microglia or in the macrophage 
lineage. As these mice developed a pathological phenotype, it is possible to 
hypothesize that the expression of mtSOD1 in all the elements of the neuromuscular 
unit is sufficient to cause motor neuron disease (Wang et al., 2005).  
Interestingly Yamanaka and colleagues demonstrated that diminishing the 
expression of hSOD1-G37R by a CRE-lox system did not affect the onset of the 
pathology but delayed microglial activation and slowed late disease progression 
indicating that mutant astrocytes are possible pharmacological targets to counteract 
the process of non–cell autonomous killing of motor neurons in ALS (Yamanaka et 
al., 2008). Conversely, another recent study demonstated astrocyte mtSOD1 loss in 
G85R mice delayed disease onset and prolonged the early phase of disease 
progression, without affecting the late phase, confirming SOD1 mutation-specific 
effects on ALS pathogenesis (Wang et al., 2010). 
 
Mechanisms of cell death in ALS 
The main pathological hallmark in ALS is motor neurons degeneration, presumably 
occurring through the aberrant activation of programmed cell death pathways. The 
explanation of the molecular steps leading to neuronal death may have important 
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therapeutic implications as this may uncover specific targets to interrupt the 
harmful cascade. In the following paragraphs, the main hypothesis about this topic 
will be discussed. 
 
Apoptosis 
Apoptosis is more often utilized as a synonymous of programmed cell death, given 
that one of its main characteristics is to be a highly regulated mechanism, though 
the meanings of these terms are not identical, Apoptosis is a common phenomenon 
induced either by specific insults mediated through so-called "death receptors" 
(external pathway) or by non-specific insults leading mitochondrial alterations and 
release of detrimental molecules, such as cyotchrome c (internal pathway). Both 
these pathways converge on the executioner phase of the process, which is driven 
by proteolitic enzymes called “caspases”. 
An amount of biochemical and functional evidence of activation of the apoptotic 
pathways were provided in ALS (Przedborski, 2003), since the initial observation 
that the presence of mutations switches SOD1 function from an anti- to a pro-
apoptotic role (Rabizadeh et al., 1995). However, as dying motor neurons do not 
fulfil the morphology of classic apoptosis, it is still controversial whether or not the 
identified mechanisms determine neurodegeneration (Guegan and Przedborski, 
2003). 
The Bcl-2 family of proteins plays a fundamental role in regulating apoptosis, as the 
balance between the pro- and the anti-apoptotic members determines the fate of the 
cell. Therefore, their possible involvement in ALS was explored. Initially, the 
protective action of the anti-apoptotic human protein Bcl-2 on motor neurons was 
tested in hSOD1-G93A mice overexpressing Bcl2 selectively in neurons (Kostic et 
al., 1997). Bcl2 overexpression lead to a delay in the onset of motor impairment and 
an increased lifespan (Kostic et al., 1997; Vukosavic et al., 2000) so this 
encouraging result stimulated a more accurate analysis of the different proteins of 
the Bcl-2 family and led to the observations that the expression of the antiapoptotic 
protein Bcl-2 was reduced during disease, whilst the pro-apoptotic Bax was 
upregulated (Vukosavic et al., 1999) and translocates from the cytosol to the 
mitochondria (Guegan et al., 2001). The consequence of these events is likely the 
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activation of the intrinsic apoptotic pathway, as cytochrome c release from 
mitochondria and caspase-9 activation was detected in parallel with the 
neurodegenerative process (Guegan et al., 2001).  
Recently, efforts have been performed to understand the molecular link between 
mtSOD1 and apoptosis. A great advance in this field was produced by the 
demonstration that mtSOD1 interacts with Bcl-2 at the mitochondrial surface 
(Pasinelli et al., 2004): this interaction,, as it was more recently demonstrated by the 
same authors, converts Bcl2 into a toxic protein by uncovering its pro-apoptotic 
BH3 domain (Pedrini et al., 2010).  
Taken together, these observations strongly argue in favor of the involvement of the 
intrinsic apoptotic pathway in ALS, but different studies provided evidence also for 
the activation of the extrinsic pathway. In particular, in vitro experiments 
demonstrated that motor neurons are sensitive to the toxicity of Fas, a death domain 
containing receptor (Raoul et al., 2002) and transgenic mice expressing different 
mtSOD1 displayed a chronic activation of this pathway (Ackerley et al., 2004; 
Tortarolo et al., 2003; Wengenack et al., 2004) and an increased vulnerability to it 
(Raoul et al., 2002). As previously mentioned, both the intrinsic and the extrinsic 
apoptotic pathway converge on the activation of the caspases. In ALS mouse 
models, the mRNA of some of these enzymes, namely caspase-1 (Guegan et al., 
2002; Li et al., 2000; Pasinelli et al., 2000; Vukosavic et al., 2000), caspase-8 
(Guegan et al., 2002), caspase –9 (Guegan et al., 2001) and caspase-12 (Wootz et 
al., 2004) were found upregulated (Hensley et al., 2002) and activated. Subsequent 
activation of effector caspases like caspase -3 (Vukosavic et al., 2000) and caspase-
7 (Guegan et al., 2001) was detected in the spinal cords motor neurons of hSOD1-
G93A mice. Furthermore, caspase-1 and –3 activation was revealed also in glial cell 
(Pasinelli et al., 2000), thereby suggesting that motor neurons degeneration might 
not be the only cell demise involved in ALS (Rossi et al., 2008).  
As caspase activity implies so harmful consequences, the cell has to tightly control 
this event, regulating not only their activation, but also their functionality. In 
particular, different proteins are deputed to counteract their action, namely the 
Inhibitor of Apoptosis Proteins (IAPs). In ALS, evidence of disruption at this level 
of control was reported, especially regarding the X-linked inhibitor of the apoptosis 
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protein (XIAP) (Guegan et al., 2001 2002 #256, Wootz, 2006 #164). Consistently, 
upregulating XIAP in vitro (Ishigaki et al., 2002) and in vivo (Wootz et al., 2006) 
protects neurons from mtSOD1 toxicity. 
These studies provided extensive evidence of the presence of apoptotic markers in 
ALS and therefore therapies targeted to different molecular steps of these pathways 
were subsequently delivered to transgenic mice to demonstrate whether they 
actually contribute to the pathogenesis of the disease. 
Initially, hSOD1-G93A mice were intracerebroventriculary delivered with zVAD-
fmk, a broad-spectrum inhibitor of caspases and a delay in the onset and mortality 
was observed (Li et al., 2000). Differently, intraspinal delivery of Bcl-2 through a 
recombinant adeno associated virus, failed to increase lifespan (Azzouz et al., 
2000), despite the fact that genetic neuronal Bcl-2 overexpression positively 
influenced the course of the disease in transgenic mice (Kostic et al., 1997) and 
rasagiline, which induces Bcl-2 expression, also prolonged hSOD1-G93A mouse 
lifespan (Waibel et al., 2004). Consistently, the role of the mitochondrial pathway 
seems to be important in ALS pathogenesis as minocycline, which inhibits 
cytochrome c release, delayed the onset of symptoms and mortality in transgenic 
mice (Zhu et al., 2002). Unfortunately a phase III clinical trial revealed harmful 
effects of minocycline on ALS patients (Gordon et al., 2007) 
 
ALS as a distal axonopathy: the “dying back” hypothesis 
Despite the general belief that ALS pathology is a consequence of motor neuron 
loss, some observations from both transgenic mouse models and human autoptic 
samples do not perfectly agree with this conviction. Neuronal loss in hSOD1-G93A 
transgenic mice was normally reported at 80-90 days (Chiu et al., 1995). However, 
accurate analysis revealed that these animals displayed electromyographical 
alterations at 40 days of age (Kennel et al., 1996) and that denervation of motor 
neurons from muscles occurs in early stages of the disease pathogenesis prior to 
clinical symptoms in mtSOD1 animals (Gordon et al., 2009; Lemmens et al., 2007; 
Park and Vincent, 2008) with selective loss of fast-firing neuromuscular synapses at 
50 (Frey et al., 2000; Pun et al., 2006). Evidence of neuromuscular junction 
impairment therefore appears long before motor neurons loss. Recently, a 
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systematic count of both hindlimb muscle end-plates and motor neurons were 
performed in the same animal model (Fischer et al., 2004) and a temporal sequence 
of detrimental events was identified that begins with denervation, followed by 
axonal loss and finally neuronal cell body degeneration. In the same study, autoptic 
specimens from a patient died for other causes pretty soon after the ALS diagnosis 
were analyzed. In this case, muscle fibers showed signs of denervation and 
reinnervation, with little axonal degeneration at the ventral roots level and no 
evidences of motor neurons sufferance (Fischer et al., 2004). This pattern suggests 
that ALS might be a “dying back” neuropathy where distal axonal degeneration 
occurs early during the disease, before neuronal loss and onset of symptoms.  
In agreement with these findings, early selective degeneration of fast fatigable 
motor neurons axons seems to be a pathological event shared by different animal 
models, namely hSOD1-G93A and hSOD1-G85R transgenic mice. Furthermore, 
the process was partially reverted by the local application of CNTF, which is an 
axon-protective agent (Pun et al., 2006). 
The “dying back” hypothesis has been recently strengthen by the demonstration that 
motor neuron death is not required for disease (Gould et al., 2006). In this study, 
hSOD1-G93A mice were cross-breeded with a transgenic line genetically devoid of 
Bax, one of the most important pro-apoptotic proteins. The progeny displayed a 
delayed onset of the symptoms and a prolonged lifespan. Interestingly, this positive 
effect was a consequence of the delay in neuromuscular denervation, rather than of 
motor neuron rescue from mtSOD1 toxicity. Indeed, these animals never showed a 
reduction of motor neurons number, even at the end stage of the disease (Gould et 
al., 2006).  
 
Other mechanisms of cell death: paraptosis and autophagy 
The morphological incongruences between the classic apoptosis output and the 
appearance of dying motor neurons raised further proposals on the mechanisms of 
cell death in ALS.  
Paraptosis is a programmed cell death characterized by cytoplasmic vacuolization, 
late mitochondrial swelling, gene expression- and protein synthesis-dependency 
(Sperandio et al., 2000). Since these features were described in hSOD1-G93A 
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transgenic mice (Dal Canto and Gurney, 1994), an involvement of this pathway was 
postulated. Nevertheless, this supposition has never been confirmed by further 
studies. 
Autophagy is a Greek term that means “eat itself” and in biology indicates a 
lysosomal pathway for degrading organelles and long-lived proteins, characterized 
by the formation of intracellular vacuoles called “autophagosomes”. The 
significance of this mechanism is presently uncertain, as autophagy may be indeed 
a compensatory mechanism to counteract a nutritional starvation. On the contrary, 
excessive or aberrant activation of this pathway may lead to self-digestion of vital 
components with subsequent cell death. Evidence of a role for this pathway in ALS 
is only clues and relies on the presence of cytoplasmic vacuolization and 
disorganization of intracellular organelles in ALS transgenic mice (Dal Canto and 
Gurney, 1995). Recently, an in vitro study demonstrated that motor neurons 
exposed to chronic excitotoxicity switch their demise pathway from programmed 
cell death into an autophagic mechanism (Tarabal et al., 2005). 
 
Therapy 
 
Conventional 
Despite intense research, ALS is still an incurable disease. Up to now patient care is 
mainly limited to improve the quality of life through symptomatic therapy and 
orthotic devices. The sole approved drug to counteract neurodegeneration is 
riluzole, which has only a modest effect on survival (Bensimon et al., 1994; 
Lacomblez et al., 1996; Miller et al., 1996). 
As mentioned in the previous sections, basic research studies identified several 
drugs targeting different molecular pathways and some of them (listed in (Carri et 
al., 2006)) were successfully tested in animal models. Unfortunately, none of the 
investigated molecules was able to modify the clinical outcome of the human 
disease (reviewed in (Gordon, 2005) or 
http://www.als.net/OurResearch/ClinicalTrials.aspx). This strident contrast raises 
questions about the usefulness of transgenic models to test therapeutics, although 
the discrepancy in the outcome might be explained by different pharmacokinetics 
Introduction 
 31
properties of the drugs in humans and in mice, or to different routes of delivery. 
Moreover, in transgenic mice, the timing of drug intervention is often before the 
onset of the disease whereas ALS patients receive drug only after the diagnosis, 
which is drawn up sometimes late after symptom onset. Finally, transgenic mice are 
models of fALS and, therefore, drugs targeting SOD1 toxicity might not be useful 
to treat sALS, which is the majority of the occurrences (Rothstein, 2003). 
A list of the ongoing trials is available online at the web sites http://clinicaltrials.gov or 
http://www.als.net/OurResearch/ClinicalTrials.aspx. 
 
Gene therapy 
One of the most promising therapeutic tools is represented by the use of some 
trophic factors, such as IGF-1 or VEGF (see above), although early trials have been 
controversial (Gordon, 2005), likely because of the poor delivery of these drugs to 
motor neurons. In the next years, it will be hopefully possible to use recombinant 
viruses to deliver the active molecule to the active site, as validated in animal 
models (Azzouz et al., 2004; Kaspar et al., 2003; Storkebaum et al., 2005). 
 
Cell therapy  
The aim of the abovementioned therapies is to stop the progression of the disease. 
The full functional recovery, indeed, is impossible after neuronal loss, since these 
cells are post-mitotic. A new hope to regenerate damaged neural tissues comes from 
the discovery of stem cells that are “self-renewing progenitor cells that can generate 
one or more specialized cell type”. The utility of these cells is theorically threefold: 
(a) they might indeed regenerate motor neurons; (b) they might regenerate non-
neuronal cells, considering that ALS is a non-cell autonomous disease (see above); 
(c) they might be used as bioreactors to vehiculate an in situ synthesis of therapeutic 
molecules (Klein et al., 2005). Presently, only a few trials have been presented 
using autologous transplantation of blood (Janson et al., 2001) or marrow 
mesenchimal stem cells (Mazzini et al., 2003). These preliminary studies aimed at 
testing the safety of the method and evidence of a clinical improvement is still 
lacking.  
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Current evidence sustains an anti-inflammatory and neuroprotective role of 
Peroxisome Proliferator Activated Receptors (PPARs) agonists in many 
neurodegenerative diseases like Multiple Sclerosis, Parkinson’s disease, 
Alzheimer’s disease and Amyotrophic Lateral Sclerosis (Heneka et al., 2005; Kiaei 
et al., 2005; Natarajan and Bright, 2002; Niino et al., 2001; Schutz et al., 2005; 
Shimazu et al., 2005; Yan et al., 2003; Zhao et al., 2005). 
Particularly two independent groups recently demonstrated a neuroprotective 
acitvity of Pioglitazone in a mouse model of Amyotrophic Lateral Sclerosis (Kiaei 
et al., 2005; Schutz et al., 2005). These studies provided a strong evidence for a 
neuroprotective activity of Pioglitazone, a PPARγ agonist, in the hSOD1-G93A 
mice demonstrating that Pioglitazone administered before the onset of symptoms, 
improves the pathology outcome by extending the survival and delaying the onset, 
ameliorates the motor dysfunction, reduces the weight loss and attenuates the motor 
neuron death. Pioglitazone also reduces the microglial activation and the gliosis in 
the spinal cord, decreasing the production of proinflammatory mediators like iNOS, 
NF-kB and COX2. These studies suggest that Pioglitazone, which is currently used 
in the therapy of type II diabetes, could be a promising new drug for the treatment 
of ALS. 
 
The Peroxisome Proliferator Activated Receptors  
The Peroxisome Proliferator Activated Receptors (Berger et al., 2005) are members 
of the steroid/thyroid hormone nuclear receptor superfamily, belonging to the 
family of ligand dipendent transcription factors; they regulate different aspects of 
energy balance, lipid and lipoprotein metabolism and glucose homeostasis (Berger 
et al., 2005; Evans et al., 2004). The three different isoforms of PPARs which are 
known so far, α (NR1C1), β/δ (NR1C2) and γ (NR1C3), exhibit homology in their 
amino acid sequence and structure but differ in their ligand-binding domains, ligand 
specificity, tissue distribution and biological actions. The name “Peroxisome 
Proliferator Activated Receptors” is derived form the PPARα mediated peroxisome 
proliferation in rodent hepatocytes; PPARγ and PPARβ/δ activation does not elicit 
this response. PPARs are in an inactivated state bound to co-repressor proteins in 
the nucleus; upon binding to the ligand they heterodimerize with the retinoid X 
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receptors (RXRs) and form heterodimers that can regulate gene expression through 
different mechanisms, namely the ligand-dependent transactivation, the ligand-
indipendent repression and the ligand-dependent transrespression (Ricote and 
Glass, 2007) (Fig. 1). 
 
Fig. 1 Trancriptional activities of the Peroxisome Proliferator Activated receptors. PPARs can both 
activate and inhibit gene expression. (a) Ligand-dependent transactivation. PPARs activate 
transcription in a ligand-dependent manner by binding directly to specific PPAR-response elements 
(PPRE) in target genes as heterodimers with RXR. Binding of ligand leads to the recruitment of co-
activator complexes that modify chromatin structure and facilitate assembly of the general 
transcriptional machinery to the promoter. (b) Ligand-dependent transrepression. PPARs repress 
transcription in a ligand-dependent manner by antagonizing the actions of other transcription factors, 
such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1). (c) Ligand-independent 
repression. PPARs bind to response elements in the absence of ligand and recruit co-repressor 
complexes that mediate active repression. This complex antagonizes the actions of co-activators and 
maintains genes in a repressed state in the absence of ligand. 
(Figure from Ricote M. and Glass C.K., Biochim. Biophys Acta. (2007) 1771(8):926-35.) 
 
PPARs activate transcription in a ligand-dependent manner by binding directly to 
specific PPAR-response elements (PPRE) in the promoter region of target genes as 
heterodimers with RXR. The binding of agonists leads to the recruitment of co-
activator complexes that modify chromatin structure and facilitate assembly of the 
general transcriptional machinery to the promoter. This activity enables PPARs to 
positively regulate gene networks involved in the control of lipid metabolism and 
glucose homeostasis in several tissues including adipose tissue, muscle and liver, 
ultimately influencing circulating lipid and glucose levels. In addition, PPARs also 
act directly to negatively regulate gene expression of proinflammatory genes in a 
ligand-dependent manner by antagonizing the activities of other transcription 
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factors, such as members of the nuclear factor-κB (NF-κB) and activator protein-1 
(AP-1) families (Devchand et al., 1996; Jiang et al., 1998; Lee et al., 2003; Marx et 
al., 1998; Ricote et al., 1998; Staels et al., 1998) (Fig. 1a). A major mechanism that 
underlies the ability of PPARs to interfere with the activities of these transcription 
factors has been termed transrepression and, unlike the transcriptional activity, it 
does not imply any interaction with the DNA (Fig. 1b). However despite the large 
amount of studies performed, the mechanisms whereby PPARs inhibit 
inflammatory gene expression are not completely understood. Recent studies using 
microarray analysis have shown that rosiglitazone inhibits only a subset of NF-κB 
target genes (Ogawa et al., 2005; Welch et al., 2003). This observation implies 
promoter-specificity in the mechanisms underlying transrepression. Many 
hypotheses have been suggested for the mechanisms of PPARs mediated 
transrepression, like the direct interaction of these receptors with other transcription 
factors, the regulation of Mitogen-activated protein kinase (MAPK) e c-Jun N-
terminal kinase (JNK) signalling pathways, the interaction with co-regulators and 
the co-repressor-dependent transrepression; the exact mechanism of PPARs 
mediated transrepression, however, has not still been clarified (Ricote and Glass, 
2007).  
PPARs can also suppress the transcription of a target gene through a ligand 
indipendent repression mechanism (Fig. 1c); in this case they recruit co-repressors 
that do not allow the binding of co-activators (Ricote and Glass, 2007).  
PPARs are composed by four domains with different functions: the DNA binding 
domain is highly conserved and is bound to the C-terminal region, which is 
responsible of the interaction with the ligand. The E/F domain is rather involved in 
the dimerization of PPARs with the RXRs and in the ligand-dependent 
transactivation. Finally the N-terminal domain is involved in the ligand-indipendent 
regulation of receptor activity (Kersten and Wahli, 2000); (Heneka et al., 2007). 
The interaction of agonists with their binding site determines a structural change 
which stabilizes the binding site of co-activators; the binding of antagonists, on the 
contrary, stabilizes a conformation promoting the binding of co-repressor 
complexes (Straus and Glass, 2007) (Yu and Reddy, 2007; Zoete et al., 2007). 
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It has been demonstrated that PPARs are sensors of different endogenous molecules 
(unsaturated fatty acids, eicosanoids and linoleic acid) produced by the metabolism 
of extracellular and intracellular fatty acids. It is difficult to establish which specific 
PPAR isoform is activated by these endogenous molecules in vivo, due to the low 
affinity of interaction and the low specificity of the ligands for the different 
isoforms. Furthermore, PPARs bind also to several synthetic compounds with an 
higher affinity and selectivity: among these, fibrates are PPARα agonists and are 
widely used in the treatment of hypertriglideridemia, while thiazolidinediones 
(TZD), like Rosiglitazone and Pioglitazone, are PPARγ ligands and are used in type 
II diabetes therapy (Fruchart et al., 1999; Ricote and Glass, 2007; Willson et al., 
1996). 
PPARα, β/δ and γ show distinct tissue distribution which mirrors their biological 
functions (Desvergne and Wahli, 1999; Heneka and Landreth, 2007; Willson et al., 
2001). Though their expression has been more deeply analyzed in humans 
compared to rodents, data suggest that PPARα is expressed mainly in tissues 
dedicated to fatty acids catabolism like liver, heart, kidney, large intestine and 
skeletal. PPARα indeed has the primary functions of regulating energy homeostasis, 
stimulating fatty acids and cholesterol catabolism, regulating the gluconeogenesis 
and reducing the plasma levels of triglycerides (Bright et al., 2008; Heneka and 
Landreth, 2007). PPARβ/δ is ubiquitously expressed (Escher and Wahli, 2000), it is 
activated by Very Low Density Lipoproteins (VLDL)-derived fatty acids and by 
eicosanoids (i.e. prostaglandin A1) and is involved in fatty acid oxidation in the 
muscle (Bright et al., 2008; Heneka and Landreth, 2007). PPARγ is abundantly 
expressed in the adipose tissue (white and brown) and, to a lesser extent, in the 
skeletal muscle, heart and liver, where it is activated by endogenous ligands like the 
15-deoxy prostaglandin J2 (15-d PGJ2) (Tontonoz and Spiegelman, 2008) (Heneka 
and Landreth, 2007). The primary activity of PPARγ is to stimulate the 
differentiation of adipocytes and to control the distribution of lipid metabolites in 
the tissues. Furthermore PPARγ agonists are able to reduce the plasma levels of 
glucose, probably due to the PPARγ mediated modulation of endocrine factors 
(Gervois et al., 2004; Tontonoz and Spiegelman, 2008). This property allowed the 
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development of PPARγ agonists for the therapy of type II diabetes (Gauglitz et al., 
2008; Kintscher and Goebel, 2009).  
 
Anti-inflammatory role of PPARs 
Besides the well studied activities of PPARs in metabolism and cell differentiation, 
many evidences suggest a possible role of these receptors in regulating the immune 
system. PPARs are indeed expressed in several immune cell types, including 
dendritic cells, macrophages and B and T lymphocytes. They are also present in 
epithelial cells where they play an essential role in the control of the immune 
response of mucous membranes. Worth to notice are the therapeutic effects 
demonstrated for some ligands of PPARα and PPARγ in many different models of 
inflammatory and autoimmune pathologies, namely Experimental Autoimmune 
Encephalitis (EAE) (Dunn et al., 2007), colitis (Cuzzocrea et al., 2004), allergic 
asthma (Woerly et al., 2003), edema and the carrageenan-induced pleuritis 
(Cuzzocrea et al., 2006; Straus and Glass, 2007). PPARβ/δ ligands have been less 
studied but they seem to be effective in EAE, too (Kielian and Drew, 2003). 
The molecular basis of these activities, need to be further investigated in the light of 
their possible use in therapy.  
It is well known that some ligand-dependent nuclear receptors, among these 
PPARs, can repress the expression of genes involved in the control of the 
inflammatory response through a ligand-dependent transrepression.  
PPARγ is able to negatively control the expression of the inducible nitroxide 
synthase (iNOS) induced by lipopolysaccharide (LPS) in macrophages interfering 
with the elimination of the corepressor-complex from the promoter (Pascual et al., 
2005). Furthermore, GW7845, a PPARγ ligand, represses the expression of genes 
coding for chemokines in LPS-stimulated macrophages (Ogawa et al., 2005).    
PPARα and PPARβ/δ have also been demonstrated to reduce inflammatory gene 
expression with a ligand-dependent molecular mechanism, but the molecular details 
have not yet been fully characterized (Straus and Glass, 2007). 
PPARγ is also expressed in dendritic cells where its activation inhibits the 
expression of membrane glycoproteins involved in promoting and maintaining 
inflammation (i.e. CD1a, CD40, CD83, CCR7), and of the costimulatory molecule 
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C80, of interleukin-12 (IL-12) and of other chemokines (Nencioni et al., 2002; 
Szatmari et al., 2006a; Szatmari et al., 2006b). Furthermore PPARγ seems to 
negatively regulate the immunogenicity of DC also in the absence of an exogenous 
ligand (Klotz et al., 2007). 
PPARα and PPARγ are espressed both in the T and B cells; the activation of T cells 
determines a reduction in the expression of PPARα and an increase in the 
expression of PPARγ (Cunard et al., 2002; Jones et al., 2002). 
Many studies demonstrated that PPARα agonists like fenofibrate and WY14643 are 
able to suppress the expression of Interferon γ (IFNγ) in T lymphocytes and the 
expression of interleukin-17 in activated splenocyte cultures (Cunard et al., 2002); 
the repression of IFNγ and IL-17 expression has never been observed in splenocyte 
cultures form PPARα -/- mice, thus it probably depends on PPARα (Lee et al., 
2007). 
A similar repressive activity of PPARγ agonists in human T cells and murine 
splenocytes has been observed (Cunard et al., 2002). 
Furthermore, PPARα is able to suppress the Tumor Necrosis Factor α (TNFα) 
induced expression of adhesion molecules in the vessels, suggesting a possible role 
in inhibiting the recruitment of leukocytes to the inflammation site (Marx et al., 
1999). 
In summary, PPAR agonists play a pivotal role in the inhibition of the recruitment 
of inflammatory cells.  
 
PPARs in the nervous system 
Studies performed on the nervous system of rats demonstrated that all of the three 
isoforms of PPARs are espressed during late embryogenesis, with the prevalence of 
PPARβ/δ. Nevertheless, while PPARβ/δ mantains high levels of expression also 
during the postnatal period, the amount of the isoforms α and γ decreases after birth 
(Braissant et al., 1996). 
The expression profile, which is isoform specific and highly regulated during 
development, suggests a possible role for PPARs in the CNS formation, even if this 
potential activity of PPARs has not been yet fully clarified.  
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The three isoforms of PPARs are all present in the brain and adult spinal cord. 
While PPARβ/δ is expressed in the neurons of different cerebral areas, PPARα and 
γ are localized in a lower number of regions. PPARs localization has been 
investigated also in non-neuronal cell cultures where PPARα is prevalently 
expressed in astrocytes, which present all the three isoforms in different amounts 
depending on the area and the age of the animal (Heneka and Landreth, 2007). 
PPARβ/δ is espressed also in immature oligodendrocytes where its activation 
promotes the differentiation, development and turn-over of myelin (Saluja et al., 
2001). PPARγ is the dominant isoform in microglia (Cullingford et al., 1998). 
The role of PPARs in the central nervous system is certainly inherent to lipid 
metabolism, even if this receptors are also implicated in cell migration and 
differentiation (Heneka et al., 2000; Inestrosa et al., 2005; Park et al., 2004b), in 
neuroinflammation and neurodegeneration (Heneka et al., 2000). 
 
Regulation of glial cell activation by PPARs and role in neurodegenerative 
diseases 
The CNS has always been considered an immune privileged site due to the capacity 
of the blood-brain barrier to prevent the immune cells from entrance and to protect 
the microenvironment from the changes in the blood levels of ions, amino acids, 
peptides and other substances. Nevertheless, resident glial cells like microglia and 
astrocytes are the effector of the innate immune system in the CNS and protect it 
from pathogens and injury. These cells readily activate to react to injury, modifying 
their morphology and their functions and proliferating. In particular microglia are 
normally quiescent but, when activated, can secrete pro-inflammatory cytokines, 
chemokines and oxygen reactive species, in addition to phagocyte pathogens and 
toxic debris. Astrocytes are involved in mantaining the extracellular environment 
optimal for neurons. Thus in physiogical conditions, they provide mechanic, trophic 
and metabolic support to neuronal cells. When challenged by toxic agents or 
pathogens, astrocyte, similarly to microglia, can become activated and produce 
nitric oxide and pro-inflammatory cytokines/chemokines. In such circumstances it 
has been hypothesized that glia remain cronically active and contribute to the 
neuronal damage typical of several CNS pathologies, including Multiple Sclerosis 
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(Smith et al., 2004; Sreedharan et al.), Alzheimer’s disease, Parkinson’s disease, 
Amyotrophic Lateral Sclerosis and ictus (Drew et al., 2006). 
Since the etiopathogenesis of most of these diseases is unknown, these pathologies 
represent an important challenge for the sanitary system due to the high social and 
economic expenses. The therapies available so far are most symptomatic and, 
therefore, the identification of new therapies is highly desirable.  
Recent evidence suggests that PPARs agonists could have a therapeutic potential in 
the treatment of these pathologies, thanks to their anti-inflammatory properties 
(McGeer and McGeer, 2004; Szekely et al., 2004; Wahner et al., 2007).  
All the three isoforms have been shown, indeed, to have an anti-inflammatory 
activity associated to the inhibition of glial activation.  
PPARα  
PPARα agonists have been demonstrated to reduce microglial and astrocyte 
activation in vitro. Gemfibrozil, a PPARα agonist, inhibits the induction by 
proinflammatory cytokines of NO and iNOS, NFkB and AP-1 in human astrocytes 
and murine primary astrocyte cultures (Pahan et al., 2002). Furthermore, 
gemfibrozil, when administrated with 9-cis-retinoic acid (RXR agonist), seems to 
inhibit the clinical symptoms of EAE in rodents (Lovett-Racke et al., 2004).  
Fenofibrate, in combination with 9-cis-retinoic acid, inhibits microglial production 
of NO, TNFα, IL-1β e IL-6 in an additive manner (Xu et al., 2005) and showed 
positive effects in EAE and ictus therapy (Deplanque et al., 2003; Lovett-Racke et 
al., 2004). 
PPARβ/δ 
Alhtough the activity of PPARβ/δ ligands has been less investigated compared to 
the other two isoforms, GW0742 (PPARβ/δ agonist) was reported to inhibit NO 
production in microglia and astrocyte primary cultures (Polak et al., 2005). This 
compound has been succesfully studied also on EAE animal models where it has 
been found to delay the progression of the pathology and to slightly improve the 
symptoms (Polak et al., 2005). 
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Several PPARβ/δ agonists have shown efficacy in the treatment of ictus, reducing 
the ischemic area and the oxidative stress produced in the CNS by the stroke 
(Arsenijevic et al., 2006). 
PPARγ 
Many PPARγ agonists show an inhibitory activity on glial production of pro-
inflammatory mediators. 15d-PGJ2, for instance, inhibits the production of NO, IL-
1β, and TNFα in murine microglial cultures (Koppal et al., 2000; Petrova et al., 
1999), but has also been shown to reduce the T cell proliferation and IFNγ, IL-10 
and IL-4 synthesis in EAE models (Diab et al., 2002; Niino et al., 2001). Many 
other studies on PPARγ ligands, like thiazolidinediones (Troglitazone, Ciglitazone, 
Pioglitazone) and PGA2, led to the conclusion that these molecules, similarly to 
15d-PGJ2, act both with a PPARγ-dependent mechanism and inhibiting the I-kB 
kinase activity, with subsequent reduction of NF-kB activity (Diab et al., 2002; Giri 
et al., 2004; Storer et al., 2005). These drugs, particularly Pioglitazone, have been 
succesfully studied on animal models of EAE, ictus, AD, PD and ALS and showed 
a notably ability to inhibit and control the inflammatory response, delaying the 
onset of the pathology and prolonging the survival of the animal models (Heneka et 
al., 2005; Kiaei et al., 2005; Natarajan and Bright, 2002; Niino et al., 2001; Schutz 
et al., 2005; Shimazu et al., 2005; Yan et al., 2003; Zhao et al., 2005).  
Many studies suggested that PPARγ agonists could positively influence EAE 
progression acting on the interaction between microglia and T cells and on T cells 
activation; the activity of these molecule seems to depend on the block of glial 
production of proinflammatory factors like NO, cytokines and chemokines (Diab et 
al., 2002; Kielian et al., 2004). 
Recently, the group of Bernardo reported a PPARγ-mediated inhibitory effect of 
HCT1026, a non-steroidal anti-inflammatory drug (NSAID) derived from 
flurbiprofen, on the activation of rat primary cultures of microglia (Bernardo et al., 
2005).  
Ibuprofen, another NSAID, seems to improve pathology symptoms in animal 
models of AD, reducing glial activation, amyloid deposition and neuritic dystrophy 
with a PPARγ-dependent mechanism (Lim and Dey, 2000).  
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Generally, the activity of PPARγ agonists consists not only in the inhibition of 
microglial activation with subsequent reduction of the production of pro-
inflammatory mediators, but also in the alteration of the expression of the same 
factors in astrocytes. Thus, it has been postulated that PPARγ agonists exert their 
neuroprotective activity by inhibiting the production of pro-inflammatory 
molecules, potentially neurotoxic, by monocytes and glial cells.  
Still, it is mentioned that PPARs, and particularly PPARγ, are espressed also in 
neurons and their activation could directly influence the transport and the 
transduction of these cells as well as their differentiation (Cimini et al., 2005; 
Inestrosa et al., 2005; Park et al., 2004b; Smith et al., 2004). Furthermore it has 
been demonstrated also a PPARγ-mediated neuroprotective effect, particularly in 
animal models of ischemia, through mechanisms that directly target neurons (Uryu 
et al., 2002; Zhao et al., 2006). Activators of PPARγ, administered in vivo before or 
after the onset of ischemia, reduce ischemic damage (Ou et al., 2006; Shimazu et 
al., 2005; Sundararajan and Landreth, 2004; Tureyen et al., 2007; Victor et al., 
2006). Recently Zhao and colleagues demonstrated that the expression of 
antioxidant genes catalase, SOD and GST and of genes that could improve neuronal 
resistance to ischemic and oxidative injury like LXRα and LPL, is reduced in 
neurons cultured from mice with selective neuronal PPARγ deficiency. Furthermore 
these mice showed significant increase in the infarct volume after cerebral ischemia 
(Zhao et al., 2009).  
Izawa and colleagues recently demonstrated that pioglitazone regulates the energy 
metabolism also in the brain enhancing the oxidative metabolism of glucose in 
neurons (Izawa et al., 2009). 
On these bases, it has been hypothesized that PPAR agonists could be able to exert 
a beneficial effect on the progression of chronic neurodegenerative diseases 
characterized by neuroinflammation, like ALS, inhibiting the glia-mediated 
neuroinflammatory process, directly protecting neurons, or both. 
Further studies to clarify the mechanisms of action of these receptors are certainly 
necessary, as they could identify specific signal transduction pathways controlled 
by PPARs and possible new therapeutic targets.  
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AIM 
During the last few years, a growing number of studies has demonstrated an anti-
inflammatory activity for the PPARs agonists, which in several pathological 
instances have been able to decrease the production of proinflammatory genes, 
including cytokines and chemokines (Klotz et al., 2007; Pascual et al., 2005; Straus 
and Glass, 2007). 
Based on these observations, the therapeutic impact of PPARs agonists has been 
more recently studied also in chronic neurodegenerative disorders characterized by 
neuroinflammatory processes, like Multiple Sclerosis, Alzheimer’s disease, 
Parkinson’s disease and Amyotrophic Lateral Sclerosis. In animal models of 
different neurodegenerative diseases, PPARs agonists proved to be efficacious in 
attenuating the manifestations of the pathology, and this effect was ascribed to their 
ability in reducing the production of proinflammatory mediators (Bright et al., 
2008; Deplanque, 2004; Drew et al., 2006; Heneka et al., 2007; Hirsch et al., 2003; 
Sastre et al., 2006). Particular attention was focused on the PPARγ agonist 
Pioglitazone because of its capacity to penetrate the blood brain barrier. This 
compound was shown to be beneficial in many animal models of neurodegenerative 
diseases (Combs et al., 2000; Heneka et al., 2005; Kiaei et al., 2005; Lim and Dey, 
2000; Schutz et al., 2005; Yan et al., 2003), including mice that reproduce several 
features of Amyotrophic Lateral Scerosis. Two independent groups demonstrated a 
neuroprotective acitvity of Pioglitazone on the hSOD1-G93A transgenic mouse 
model of ALS. In these studies, administration of Pioglitazone, before the onset of 
the symptoms, improved the motor performance and reduced the weight loss, 
attenuated motor neuron death and increased the survival delaying the onset. These 
effects were associated to reduced microglial activation and gliosis in the spinal 
cord as well as decreased production of proinflammatory mediators like iNOS, NF-
kB and COX2. 
As yet, different mechanisms of PPARs activation have been described, some of 
which directly related to gene transcription and other interfering with the activity of 
other transcription factors (Ricote and Glass, 2007), but the signalling pathways 
involved and the specific events responsible for their neuroprotective activity have 
not been clearly elucidated. 
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On these bases, the aim of my work was to study the transcriptional activity of the 
PPAR systems in vivo, in the central nervous system, throughout the course of ALS 
with the aim of clarifying the stage of the disease at which the activity of this class 
of receptors becomes relevant for the pathology. The comprehension of the 
molecular mechanisms that are responsible for their neuroprotective activity could 
then possibly lead to identify new targets for unprecedented therapeutic approaches.        
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METHODS 
Animal models 
hSOD1-G93A mice 
The transgenic mouse model of ALS used in this study, the hSOD1-G93A animals, 
has been generated by Mark Gurney and his collaborators in 1994 (Gurney, 1994; 
Gurney et al., 1994). hSOD1-G93A mice ubiquitously express a high copy number 
of the glycine to alanine base pair mutation at the 93rd codon of the cytosolic human 
Cu/Zn superoxide dismutase gene (Gurney, 1994). These mice develop progressive 
motor neuron disease that recapitulates in many aspects the human pathology: the 
symptoms manifest around 90 days of age when the animals show hindlimb 
weakness, the development of tremors and loss of weight (Chiu et al., 1995; Gurney 
et al., 1994). Motor functions progressively decrease leading to complete paralysis 
and death at around 130-150 days of age. At the histopathological level, the 
phenotype is associated to selective degeneration of spinal motor neurons, protein 
inclusions in surviving motor neurons and significant loss of myelinated axons 
originating from the ventral horns of the spinal cord. Female hSOD1-G93A are 
infertile, so the transgenic mice hSOD1-G93A are maintained in hemizygosity in the 
mixed background C57Bl6/SJL by mating of hSOD1-G93A mice with wild type 
C57Bl6/SJL females. 
PPRE-Luc mice 
The transgenic mouse line PPRE-Luc, generated in our laboratory, is a reporter 
mouse ubiquitously expressing the gene coding for the firefly luciferase under the 
control of a promoter responsive to PPARs. This model allows to evaluate the 
activation of PPARs and represents a novel opportunity for the characterization of 
PPAR transcriptional activity in physiopathological conditions.  
Transgenic PPRE-Luc mice were generated by pronuclear injection of the pMAR-
PPRE5X-tk-Luc-MAR transgene, which contains copies of the PPAR responsive 
element (PPRE) and the minimal promoter of the thymidine kinase, into murine 
oocytes (Ciana et al., 2007). Matrix attachment regions (MAR) from chicken 
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lysozyme (Stief et al., 1989) flanking the constructs were previously described as 
elements indispensable to obtain the generalized expression of the reporter (Ciana et 
al., 2001). 
 
Fig. 1: pMAR-PPRE5X-tk-Luc-MAR transgenic construct: the selected PPRE is the most 
responsive to the PPARs and is repeated five times in tandem and cloned upstream the 
minimal promoter of thymidine kinase (tk), controlling luciferase expression. The MAR 
sequences flanking the construct are needed to obtain an ubiquitous expression of the 
reporter. 
Generation of hSOD1-G93A+/-;PPRE-Luc+/- mice 
Eterozygous hSOD1-G93A female mice were crossed with omozygous PPRE-Luc 
male mice to obtain hSOD1-G93A+/-;PPRE-Luc+/- and hSOD1-G93A-/-;PPRE-Luc+/- 
mice which were used for subsequent experiments. 
 
Mice genotyping 
Tail biopsies (1-2 mm) were lysed in 100 µl of lysis buffer (10 mM TRIS/HCl pH 
9.0; 50 mM KCl; 0.45% Nonidet P40; 0.45% Tween 20; 0.1 mg/ml PK (proteinase 
K)) for 12 hours. The samples were then heated at 95°C for 10 min to inactivate the 
PK and then centrifuged at 13200 rpm for 20 min to precipitate the remaining tissue. 
The supernatant containing the genomic DNA was then used for subsequent PCR 
analysis.  
The primers used for hSOD1-G93A amplification were:  
5’ SOD: 5’ CAT CAG CCC TAA TCC ATC TGA 3’ 
3’ SOD: 5’ CGC GAC TAA CAA TCA AAG TGA 3’ 
IL-2 primers used in the same reactions as internal control were the following:  
5’ IL: 5’ CTA GGC CAC AGA ATT GAA AGA TCT 3’ 
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3’ IL: 5’ GTA GGT GGA AAT TCT AGC ATC ATC C 3’ 
The reaction mixture was the following: 0.4 µM primers, 200 µM dNTPs, 1X DNA 
Pol buffer and 32 U/ml DyNAzyme II DNA polimerasi. 0.5-1 µl of the supernatant 
of the lysed tail were added to 25 µl of reaction mixture. 
After 35 cycles (30 sec at 95°C, 30 sec at 60°C, and 30 sec at 72°C), the products 
were analyzed on 2% agarose gels stained with ethidium bromide in TAE buffer 
(0.04 M Trizma Base; 0.02 M acetic acid; 1 mM EDTA; 0.5 µg/ml ethidium 
bromide).  
The amplicons of hSOD1-G93A and IL-2 were fragments of 250 bp and 320 bp 
long, respectively. The amplification of genomic DNA from transgenic animals 
produced both the bands, while the PCR of genomic DNA from non transgenic 
animals resulted only in the 320 bp IL-2 band.  
Cellular models 
The NSC-34 cells produced by Cashman et al. (Cashman et al., 1992) have emerged 
as the most promising alternative to primary motor neurons. NSC-34 is a hybrid cell 
line produced by fusion of motor neuron enriched, embryonic mouse spinal cord 
cells with mouse neuroblastoma. The NSC-34 cell line has many of the 
morphological, physiological and neurochemical properties of motor neurons 
[reviewed in (Matusica et al., 2008)], including motor neuron-like functional 
responses to numerous growth factors (He et al., 2002; Turner et al., 2004; Usuki et 
al., 2001). The majority of differentiated NSC-34 cells resemble cultures of motor 
neurons. Typically, these are large cells with multi-polar neurite projections, with a 
small percentage of the cells exhibiting a flat fibroblast-like morphology with short 
neuritic projections. Thus, the NSC-34 cells are the best available model for the in 
vitro investigation of many aspects of motor neuron biology, including studies on 
ALS. NSC-34 cells were grown in DMEM 10% Fetal Bovine Serum, L-Glutamine 2 
mM, Sodium Pyruvate 1 mM, supplemented with Penicillin, streptomycin and anti-
mycotic solution. Cells were splitted when the 70% confluence was reached. 
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Transfection of NSC-34 cells with the hSOD1-G93A expression vector 
Cells were plated in 24-well plates until 70% of confluence. The medium was 
changed 2 hours before the transfection. For each well of a 24-well plate, 0.4 µg of 
pIRESGreen1 hSOD1-G93A or the empty vector were mixed with 3.6 µl of FuGene 
previously incubated with the growth medium (DMEM) for 5 min in a total volume 
of 20 µl, and left to incubate for 15 min at room temperature. The DNA-FuGENE 
complexes were then added to the cells. After 48 hours the cells were lysed and 
RNA wase xtracted for subsequent RT-PCR analysis. 
Luciferase enzymatic assay 
To quantify the luciferase activity in tissue extracts from luciferase reporter mice, 
animals were anesthetized with 78% ketamine and 15% xilazine in bdH20 and 
sacrificed. The tissues of interest were collected and immediately frozen in dry ice 
and stored at -80°C. Tissues were omogenized in 200 µl of lysis buffer (100 mM 
KPO4 pH 7.8, containing 1 mM dithiothreitol; 4 mM EGTA; 4 mM EDTA and 0.7 
mM phenylmethylsulfonyl fluoride) using a TissueLyser (QIAGEN GmbH, Hilden, 
Germany) with 3 cycles of 10 sec with a 22 Hertz frequency. After one cycle of 
freezing-thawing to promote the breaking of cellular membranes the samples were 
centrifuged at 5900nrpm for 30 min at 4°C. The supernatants containing the protein 
extracts were then collected and used for subsequent luciferase enzymatic assay. 20 
µl of tissue extract were added to the wells of a white 96 multiwell at 37°C, then the 
plate was positioned inside the luminometer (LUMAT LB 9501 Berthold) that 
injected sequentially 100 µl of a solution containing luciferine (470 µM Luciferine 
(Promega); 20 mM Tricine (Gibco); 0.1 mM EDTA (Merk); 1.07 mM 
(MgCO3)4Mg(OH) x 25H2O (Sigma); 2.67 mM MgSO4 x 7H2O (Merk) in bdH2O 
pH 7,8 with 33.3 mM DTT (Boheringer Mannheim) and 530 µM ATP (Boheringer 
Mannheim) in each well. The luminometer detected the photon emission (RLU, 
Relative Luminescence Unit) coming from the enzymatic reaction between the 
luciferase inside the samples and the luciferine in the buffer 10 sec after having 
injected the substrate in each well of the plate.  
The values of RLU were then normalized on the total protein content quantified 
with the Bradford Protein Assay.  
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Bradford Protein Assay 
The Bradford Protein Assay is a colorimetric assay in which the interaction between 
the basic groups of the protein present in the sample and the Comassie reagent in an 
acidic environment leads to the development of a blue color. The intensity of the 
blue color is directly proportional to the amount of protein present in the sample.  
The standard curve is based on serial dilutions of bovine albumine (BSA, Bovine 
Serum Albumine-Pierce) with the following concentration: 0,500-0,375-0,281-
0,211-0,158-0,119-0,089-0,067 µg/ml.  
200 µl of Comassie reagent were added to each well of a 96 well plate, then 4 µl of 
each point of the standard curve or of the unknown sample were added to the 
Comassie contained in each well. Every sample was analyzed in triplicate. The O.D. 
of each sample was read with a spectrophotmeter (Microplate reader, Bio-Rad) at 
the wave lenght of 595 nm.  
The concentration of the samples were then obtained referring to the BSA standard 
curve.  
Analysis of the expression of PPARα, PPARβ/δ and PPARγ target 
genes in the spinal cord of hSOD1-G93A mice 
 
RNA extraction from spinal cord 
hSOD1-G93A mice and their non-transgenic littermates were sacrificed and the 
spinal cord was immediately collected, frozen in dry ice and stored at -80°C. 
The RNA was extracted using the RNA extraction kit RNeasy Mini kit (Qiagen) 
accordingly to manifacturer’s instructions. Briefly: 
1. the entire spinal cord was homogenized (5% w/v) in RLT Buffer with 1% β-
mercaptoethanol using a Tissue Lyser (Qiagen) with 2 cycles of 15 sec with a 
frequency of 10 Hz. 
2. 600 µl of the homogenized sample were transferred to a new tube and the 
remaining sample was stored at -80°C for potential further utilization. 
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3. The samples were then centrifuged for 3 min at 16100 x g and the supernatants 
were carefully removed by pipetting and transferred to a new microcentrifuge tube. 
Only these supernatants (lysates) will be used in subsequent steps.  
4. 1 volume of 70% ethanol was added to the cleared lysate, and immediately mixed 
by pipetting. 
5. up to 700 µl of the sample were transferred to an RNeasy spin column placed in a 
2 ml collection tube. The samples were then centrifuged for 15 sec at 8000 x g . The 
flow-through was discarded and the procedure was repeated with the remaining 
lysate-ethanol mixture. 
6. 350 µl of Buffer RW1 were added to the RNeasy spin column and the samples 
were centrifuged for 15 sec at 8000 x g to wash the spin column membrane. The 
flow-through was discarded. 
7. 80 µl of DNase (Qiagen; resuspended in 550 µl of bdH2O and diluted 1:8 with 
RDD buffer (provided)) were added to each column and the samples were left to 
incubate for 15 min.  
8. 350 µl of Buffer RW1 were added to the RNeasy spin column and the samples 
were centrifuged for 15 sec at 8000 x g to wash the spin column membrane. The 
flow-through was discarded. 
9. the collection tube placed under the column was substituted with a new one and 
500 µl of RPE buffer (provided, ethanol addiction is required at the first use, as 
indicated by the manufacturer) were added to the column and the samples were 
centrifuged for 15 sec at 8000 x g to wash the spin column membrane. The flow-
through was discarded. 
10. another washing step with RPE Buffer identical to the previous one was 
perfomed. 
11. the columns were then placed on a new tube and centrifuged for 1 min at 16100 
x g to dry the excess of RPE Buffer. 
12. The columns were then placed on the collection tube and 40 µl of RNase free 
water (provided) were added to each column. The samples were then centrifuged for 
15 sec at 8000 x g. The RNA is in the flow-through. To increase the yeld fo RNA, 
as suggested by the manifacturer, the flow-through was pipetted again on the 
membrane inside the column and the centrifugation step was repeated. The RNA 
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obtained was an aqueous solution that was stored at -80°C. The RNA concentration 
was quantified using a Nanodrop-1000 Spectrophotometer (Thermo Scientific). 
 
RNA extraction from mouse motor neuron NSC-34 cell line 
The NSC-34 cells transiently transfected with the hSOD1-G93A or the empty vector 
pIRESGreen1 were grown on 24 well plates, transfected and lysated 48h after the 
transfection. Briefly 5 wells of the 24 well plate were disrupted with 350 µl of RLT 
lysis buffer supplemented with 1% β-Mercaptoethanol. The collected lysate was 
then homogenized by 5 passages through a 21 gauge needle fitted to a RNAse-free 
syringe. 
Then, the same procedure used for the spinal cord RNA extraction was followed 
(from step 4 to 12). 
 
Reverse transcription and cDNA synthesis 
1.5 µg of random primers (Promega) were added to 1 µg of RNA in a total volume 
of 15 µL. The samples were heated at 75°C for 5 min to allow RNA denaturation for 
random primers binding. 10 µl of the reaction mixture (dNTPs 1.25 mM, MMLV 
RT 20 U/ µl, 1X MMLV RT Buffer in bdH2O) were added to each sample and they 
were left to incubate for 1 h at 37°C to allow first strand cDNA synthesis. 
The samples were then heated to 75°C for denaturation and then placed on ice and 
stored at -80°C. 
 
RT-PCR for PPARs target genes 
The reaction mixture was the following: 0.8 µM primers, 200 µM dNTPs, 1X DNA 
Pol buffer and 10 U/ml GoTaq DNA polimerasi. 1 µl of cDNA was added to 24 µl 
of reaction mixture. 
The primers used for each gene are outlined in Table 1. 
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Table 1 
Gene Primers 
Medium chain Acyl CoA 
Dehydrogenase (MCAD) 
FW: 5’ GAAGAGTTGGCGTATGGG 3’ 
REV 5’ GCGGAGGGCTCTGTCACACA 3’ 
Acyl CoA synthetase long-
chain family member 6 
(Acsl6) 
FW: 5’ GAGGACAGGACAAAGGAGG 3’ 
REV: 5’ CACGACAATGCCAACCAAAAAG 3’ 
Lipoprotein lipase (LPL) FW: 5’ CACCGGGAGATGGAGAGCAAA 3’ 
REV: 5’ CCCAACTCTCATACATTCCC 3’ 
Catalase (Bernardo et al.) FW: 5’ CCTCGTTCAGGATGTGGTTT 3’ 
REV: 5’ GGCATCCCTGATGAAGAAAA 3’ 
Glutathione S-transferase 2 
(Gsta2) 
FW: 5’ AAGACTGCCTTGGCAAAAGA 3’ 
REV: 5’ GCCAGTATCTGTGGCTCCAT 3’ 
Peroxisome Proliferator 
Activated Receptor gamma 
coactivator 1 alpha 
(PGC1alpha) 
FW: 5’ CTTCTTGCTCTTCCTTTAACTCTC 3’ 
REV: 5’ CTTTCTGCTTCTGCCTCTCTCTC 3’ 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
FW: 5’ ACGACCCCTTCATTGACC 3’ 
REV: 5’ TGCTTCACCACCTTCTTG 3’ 
 
The PCR reaction was optimized for each different gene; the linear range of 
amplification was calculated by performing the amplification at different cycles and 
then choosing the number of cycles comprised in the range in which the 
amplification was exponential. Particularly a large scale volume master mix of the 
PCR reaction was prepared and the proper amount of cDNA was added, then equal 
25 µl aliquots were measured into 10 tubes. The reaction was initiated, with one 
tube removed every two cycles starting at 16 cycles. 
The thermal profle used for each gene are outlined in Table 2. 
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Table 2 
Gene Thermal profile Amplification 
fragment size 
MCAD (95°C 45 sec, 51 °C 45 sec, 72°C 1 min) 
x 27 cycles for spinal cords 
167 bp 
Acsl6 (95°C 45 sec, 55°C 45 sec, 72°C 1 min)  
x 26 cycles for spinal cords 
240 bp 
LPL (95°C 45 sec, 55°C 45 sec, 72°C 1 min) 
x 30 cycles for spinal cords  
x 28 cycles for NSC34 cells 
283 bp 
Cat (95°C 45 sec, 53°C 45 sec, 72°C 1 min) 
x 24 cycles for spinal cords 
x 30 cycles for NSC34 cells 
352 bp 
Gsta2 (95°C 45 sec, 53°C 30 sec, 72°C 1 min) 
x 39 cycles for spinal cords 
345 bp 
PGC1alpha (95°C 1 min, 63°C 45 sec, 72°C 1min)  
x 27 cycles for spinal cords 
x 41 cycles for NSC-34 cells 
402 bp 
GAPDH (95°C 1 min, 53°C 1 min, 72°C 1 min)  
x 22 cycles for spinal cords 
x 21 for NSC34 cells 
691 bp 
 
The products were analyzed on 3% agarose gels (1% for GAPDH, 2% for PGC1α) 
stained with ethidium bromide in TEB buffer (0.09M Tris; 0.096 M Boric acid; 0.01 
M EDTA pH 8.4).  
To perform a semi-quantitative assessment of the relative gene expression, 12,5 µl 
of each RT-PCR product was electrophoresed on agarose gel and stained with 
ethidium bromide. The optical density of each amplified band was calculated using 
the Gel Doc (BioRad) processing program and numerically expressed as the relative 
density in comparison to the optical density of the background. Furthermore, all 
results were normalized to the expression of the housekeeping gene Glyceraldehyde 
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3 phosphate dehydrogenase (GAPDH), which is constitutively expressed in all cells 
and serves therefore as an internal standard. Under these conditions, gross 
quantitative estimations were possible and broad differences in mRNA expression 
could be detected.  
Nuclear and cytoplasmic protein fractionation from spinal cord 
Frozen spinal cords were weighed and cut in small pieces with a scalpel on ice. The 
tissue was then omogenized in 3 ml per gram of tissue of hypotonic lysis buffer (20 
mM Hepes pH 7.5; 5 mM NaF; 10 µM Na2MoO4; 0.1 mM EDTA; 1mM DTT; 0.01 
% NP-40) and incubated on ice for 15 min. The samples were then centrifuged at 
850 x g for 10 min at 4 °C.The supernatant obtained from this centrifugation 
represents the cytosolic fraction which was transferred to another tube. 
The pellet was resuspended in 500 µl of hypotonic lysis buffer without DTT and 
NP-40. The samples were then incubated on ice for 15 min, then 50 µl of 10% NP-
40 were added to the samples and the tubes were centrifuged at 14000 x g for 30 sec 
at 4°C. The supernatant obtained was the cytosolic fraction and was transferred to 
the tube together with the fraction previously isolated. The cytosolic fraction then 
was stored at -80°C. The pellet was then resuspended in 50 µL of extraction buffer 
(10 mM Hepes pH 7.9; 0.1 mM EDTA; 1.5 mM MgCl2; 420 mM NaCl; 0.5 mM 
DTT; 0.5 mM PMSF; 1 µg/ml Pepstatin A; 1 µg/ml Leupeptin; 10 µg/ml Aprotinin; 
20 mM NaF; 1 mM Βeta-Glycerophosphate; 10mM Na3OV4; 25% Glycerol). 
The samples were vortexed at high speed and incubated at 4°C in slow agitation for 
30 min.  
The samples were then centrifuged at 14000 x g for 10 min at 4°C, the supernatant 
was the nuclear fraction and was stored at -80°C.  
The cytoplasmic and nuclear extracts were then quantified with the Bradford Protein 
assay and used for subsequent assay.  
 
Quantitative assay for PPAR DNA binding  
Nuclear presence of PPARα, PPARβ/δ and PPARγ was assayed using an enzyme-
linked immunosorbent assay-based PPARα,-δ,-γ Transcription Factor Assay Kit 
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(Cayman Chemical). Nuclear proteins were extracted from spinal cords of hSOD1-
G93A mice and non transgenic littermates according to the manufacturer's 
instructions and protein concentration was determined by the Bradford method using 
BSA as standard, as previously described. A double-stranded DNA sequence 
containing the PPAR response element was linked to the bottom of wells (96-well 
plate). PPARs within the nuclear fraction bound specifically to this sequence and 
isoforms were detected using primary antibodies directed against the individual 
PPARs. Clarified cell lysates were supplied for each PPAR isoform and acted as 
effective positive controls for PPAR DNA binding. Specificity of binding was also 
demonstrated using wells with no nuclear protein added and wells with positive 
control and an excess of consensus oligonucleotide (WT oligonucleotide) added 
which competes with the oligonucleotide bound to the wells. In these wells, no 
binding was detected. Binding activity was measured at 450 nm (minus the blank).  
Experimental procedure: 
 
The plate and the buffers were equilibrated at room temperature prior to opening.  
The binding buffer (25% 4X Transcription Factor Binding Assay Buffer, 73% 
bdH2O, 1& Reagent A, 1% 300mM DTT) was first added to the wells as follows: 
Blank and non-specific binding wells: 100 µl  
WT oligonucleotide plus positive control wells: 80 µl 
Positive control or sample wells: 90 µl 
Then 10 µl of WT oligonucleotide and 10 µl  of positive control were added to the 
WT oligonucleotide plus positive control wells; 
10 µl of positive control or of the samples to be analysed were added to the 
designated wells; 
The plate was sealed with the cover provided and incubated over night at 4°C. The 
wells were emptied and washed 5 times with 200 µl of 1X Washing Buffer 
(provided, to be diluted 1:400 in bdH2O 0,05% Tween-20). 
100 µl of primary antibody specific for the individual PPARs diluted 1:100 in 1X 
Antibody Binding Buffer (ABB; provided, to be diluted 1:10 with bdH2O) were 
added to each well except for the blank and the plate was incubated 1 h at room 
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temperature with agitation. The wells were emptied and washed 5 times with 200 µl 
of 1X Washing Buffer. 
100 µl oh HRP-secondary antibody diluted 1:100 in 1X ABB were added to each 
well except for the blank and the plate was incubated for 1 h at room temperature. 
The wells were emptied and washed 5 times with 200 µl of 1X Washing Buffer. 
100 µL of Developing Solution (provided) were added to each well and the plate 
was incubated with gentle agitation and protected from light, at room temperature, 
until the wells turn medium to dark. 
After 45 min the reaction was stopped with 100 µl of Stop Solution (provided) 
added to each well and the plate was quickly positioned in a microplate reader 
(Microplate reader, Bio-Rad) and the colorimetric reaction was quantified at the 
wave lenght of 450 nm.  
The data obtained were then expressed like medium optical density (O.D.)/µg of 
proteins. 
 
Immunohistochemistry 
 
hSOD1-G93A mice and non-transgenic littermates were sacrificed and the spine 
was fixed in parafomaldehyde 4% p/v in Phosphate buffered saline (PBS: 142 mM 
NaCl, 2.5 mM NaH2PO4, 7.5 mM Na2HPO4 pH 7.4) for 24 h. The spinal cord was 
extracted and dehydrated through the following ethanol-xilene series: 
Phosphate buffer (PB) 24h 2 times 
70% ethanol 24 h 
80% ethanol 24 h 
95% ethanol 1 h 3 times 
100% ethanol 1 h 3 times 
Xilene 45 min 4 times 
 
The tissue was then paraffin embedded and the lumbar tract was cut in 10 µm slices 
using a microtome (Boeckeler).  
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The sections were then deparaffinated trough the following ethanol-xilene series: 
Xilene 5 min 3 times 
100% ethanol 5 min 3 times 
95% ethanol 5 min  
75% ethanol 5 min 3 
50% ethanol 5 min 
The sections were the rehydrated in bdH2O (5 min) and the antigen retrival was 
performed by boiling them in 10 mM citrate buffer pH 6 for 15 min in a microwave 
oven. The sections were then water-cooled for 30 min. The sections are then washed 
with bdH2O and permeabilized in TNT buffer (100 mM Tris-HCl pH 7.5, 150 mM 
NaCl (TN) 0.05 % Tween 20) for 5 min. The samples are then incubated in a 
blocking solution (TNB: 0,5% p/v of Blocking provided with the amplification kit 
Tyramide Amplification System-TSA (Perkin Elmer) in TN) for 1 h to saturate 
aspecific binding sites.   
The sections were then incubated with the primary antibody diluted in TNB 
overnight. 
Primary antibodies against PPARα, PPARβ/δ,PPARγ, SMI32 (neuronal marker 
which stains non-phosphorylated neurofilaments), GFAP (Glial Fibrillar Acidic 
Protein: astrocyte cyotskeletal marker) and Licopersicum esculentum Lectin (which 
stains microglia) have been used at the working dilutions indicated in the section 
“Materials”.  
The sections were then washed 3 times with TNT and incubated with the fluorescent 
secondary antibody diluted in TNB at room temperature and protected from the 
light. Secondary antibodies utilized and their working dilutions are indicated in the 
section “Materials”.  
The sections were washed 3 times with TNT and incubated with Hoechst 33342 
1µg/mL in PBS for 15 min to stain the cellular nuclei.  
The samples were finally washed 3 times with TNT and cover glass were mounted 
on the sections using the Dako mounting medium (Dako Mounting Medium).  
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Microscopy 
The staining was captured with a 40X magnification using a Zeiss Axioskop 40, 
equipped with a digital camera (Nikon Coolpix 9900).  
The immunofluorescence images in the ventral horns of the spinal cord sections 
were recorded. 
 
Quantification of the nuclei positively stained for PPARs 
 
The quantification of the number of nuclei positively stained for PPARs in the 
different cell types was performed manually by counting the number of cells which 
had a predominant nuclear staining compared to the cytoplasm in the ventral horns 
of spinal cord sections of hSOD1-G93A mice and, in the case of motor neurons, 
their non transgenic littermates. The results were reported as percentage of the total 
number of cells considered. 
Quantification of the nuclear fluorescence of PPARγ  
The quantification of the nuclear fluorescence of PPARγ was performed using 
ImageJ, a software from NIH. The application measures the signal intensity per 
pixel in a previously identified region of interest (ROI). The result is the mean of all 
the signals reported in that area. ROIs of 1188 pixels were created on the images of 
lumbar spinal cord sections previously stained for PPARγ and the neuronal marker 
SMI32. The fluorescence intensity of both PPARγ and the marker Hoechst 33342 
were determined in the nucleus of motor neurons and non neuronal cells. Since 
Hoechst 33342 is a fluorescent stain which binds the DNA, we considered its 
intensity as a measure of the quantity of DNA. Since the nuclei of motor neurons are 
bigger that those of non neuronal cells, their DNA content is more diluted. Thus, the 
intensity of fluorescence coming from PPARγ labeling has been normalized on the 
intensity of the fluorescence signal of Hoechst 33342. 
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Statistical analyses 
Statistical analysis data were obtained by means of analysis of variance (ANOVA) 
using GraphPad Software (PRISM) (San Diego, CA). Difference between groups 
was determined by Bonferroni comparision; a P<0.05 was considered statistically 
significant. 
 
 
MATERIALS 
Acetic acid     Riedel-de Haen 
Agarose     Sigma Aldrich 
Aprotinin     Sigma Aldrich 
ATP      Boheringer Mannheim 
BSA (Bovine serum albumin)   Pierce 
Beta-glycerophosphate    Sigma Aldrich   
Boric acid     Sigma Aldrich 
Citric acid      Sigma Aldrich 
Comassie     Sigma Aldrich 
dNTPs (deoxynucleotide triphosphates) Amersham Pharmacia Biotech AB 
DTT (Ditiotreithol)    Sigma Aldrich 
EDTA (ethylendiamminotetraacetic acid) Sigma Aldrich 
EGTA (ethylene glycol tetraacetic acid)  Sigma Aldrich 
Ethanol, absolute    Merck 
Ethidium bromide    Sigma Aldrich 
FuGene     Roche 
Glycerol     Fluka 
Hepes      Sigma Aldrich   
Hoechst 33342     Sigma Aldrich  
Hygromycin B     Sigma Aldrich  
KCl      Merck 
Ketamine     Intervet Productions 
K2HPO4     Merck 
KH2PO4     Merck 
MgCl2      Merck 
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(MgCO3)4 Mg(OH)2 x 2 H2O   Sigma Aldrich  
MgSO4 x 7H2O     Merck 
Mounting medium    Dako 
Leupeptin     Sigma Aldrich  
Licopersicum esculentum Lectin  Sigma Aldrich     
Luciferine     Promega 
NaCl      Sigma Aldrich  
NaF      Farmitalia Carlo Erba 
Na2HPO4     Merck 
NaH2PO4     Merck 
Na2MoO4     Merck 
Na3OV4     Sigma Aldrich   
NP-40 (Nonidet P-40)    Sigma Aldrich   
Paraffin     Merck 
Paraformaldehyde    Fluka 
Pepstatin A     Sigma Aldrich   
(PMSF )Phenylmethylsulfonil fluoride  Sigma Aldrich  
Primers     Sigma Aldrich   
Proteinase K     Sigma Aldrich  
Random primers    Promega 
MMLV Retrotranscriptase (H-)point mutant Promega   
Sodium citrate     Sigma Aldrich   
Taq GoTaq polimerase    Promega 
Taq polimerase     GeneSpin 
Transcription Factor PPARs assay  Cayman 
Tricine      Gibco 
TRIS HCl     Sigma Aldrich   
Trizma base     Sigma Aldrich  
TSA Amplification kit    Perkin Elmer 
Tween 20     Sigma Aldrich   
Xilazine     Rompun (Bayer) 
Xilene      Merck 
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Primary antibodies: 
Neurofilament H Non-Phosphorylated (SMI 32) Monoclonal Antibody (1:500) Sternbergen 
Monoclonals Incorporated)  
Anti-PPARα polyclonal antibody (1:100)  Affinity Bioreagents 
Rabbit serum anti-PPARβ (1:300) Kind gift from Dr. Herve Schon – 
University of Metz - France  
Anti-PPARγ polyclonal antibody (1:100)  Affinity Bioreagents 
Mouse anti-GFAP 488 conjugated (1:1000)  Chemicon 
 
Secondary antibodies  
Goat anti-mouse 488 (1:200)    Molecular Probes 
Donkey anti-rabbit Cy3 (1:400)    Jackson Immuno Research 
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RESULTS 
As mentioned in the “Introduction” section, increasing evidence demonstrates that 
PPARγ plays neuroprotective and anti-inflammatory roles in various 
neurodegenerative diseases, including ALS (Heneka and Landreth, 2007). 
Furthermore several indications suggest that PPARs are implicated in a number of 
signaling transduction pathways potentially involved in neuronal activity and 
survival, suggesting that dysfunction of these receptors may influence the neuronal 
pathophysiology. However the specific mechanisms by which PPARs exert their 
neuroprotective roles remain to be further elucidated. 
 
Analysis of PPAR transcriptional activity in the spinal cord of 
hSOD1-G93A mice 
To investigate the activity of Peroxisome Proliferator Activated Receptors in the 
central nervous system during the progression of Amyotrophic Lateral Sclerosis, we 
decided to analyse the transcriptional activity of these receptors in the spinal cord of 
hSOD1-G93A mice during the course of the disease taking advantage of the 
reporter PPRE-Luc mouse line (Ciana et al., 2007), available in our laboratory, in 
which the luciferase reporter gene is expressed under the control of a promoter 
responsive to PPARs.  
Omozygous female PPRE-Luc mice (PPRE-Luc +/+) were crossed with 
eterozygous male hSOD1-G93A+/- animals, obtaining emizygous PPRE-Luc mice 
(PPRE-Luc +/-) transgenic or non transgenic for the human mutated SOD1 
(hSOD1-G93A).  
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The animals were sacrificed at the critical stages of the pathology: 30 days (pre-
symptomatic stage), 75 days (intermediate stage in which the motor neuron starts to 
detach form the motor plaque), 100 days (onset of the symptoms) and end stage, i.e. 
when the mice are unable to right themselves within 30 sec when being placed on 
their side. Since the endstage of hSOD1-G93A mice is around 120-140 days of age, 
non-transgenic mice were sacrificed at 30 days, 75 days, 100 and 130 days as 
controls. The cervico-thoracic and thoraco-lumbar spinal cord, the motor cortex, the 
hippocampus, the thalamus and the cerebellum were collected. We collected also 
the liver, the kidney and the lung to verify possible influences by the disease in the 
peripheral organs, which are not involved in the pathological process. The 
harvested tissues were immediately frozen at -80°C until subsequent analysis. To 
reduce the variability linked to the gender we focused our studies only on female 
mice. Five mice per each stage of the pathology were analysed.  
The data showed that, in non-transgenic mice, PPAR activation is fairly constant 
throughout the progression of the pathology in all CNS areas taken into 
consideration, with the exception for non- statistically significant differences. The 
hSOD1-G93A mice showed a similar trend in the spinal cord, motor cortex and 
cerebellum until the onset of the pathology at 100 days, then luciferase activity 
increases abruptly and significantly at the end stage (p<0.001). The hippocampus 
and thalamus showed non-significant decreases in luciferase activity from 30 to 100 
days, then the signal increased at the end stage (p<0.001) [Fig. 1]. 
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Fig. 1: Evaluation of PPARs activity in the different CNS areas of hSOD1-G93A mice at the 
different stages of the pathology. The cervico-thoracic and thoraco-lumbar spinal cord, the motor 
cortex, the cerebellum, the hippocampus and the thalamus of female PPRE-Luc +/- mice transgenic 
or not for the mutated (G93A) human SOD1 were harvested at the critical stages of the pathology: 
30, 75, 100 days (d=days), end stage (ES). The luciferase activity was normalized to the total protein 
content. The data are expressed as RLU (Relative Luminescence Unit)/µg of total proteins ± SEM. 
Two-way analysis of variance (ANOVA) followed by Bonferroni Post Test was used to compare the 
means of the different stages in the transgenic and non transgenic groups. *=p<0,05 , **=p<0,01 , 
***=p<0,001.  
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The luciferase activity in the peripheral tissues was variable but we never observed 
the increase in luciferase activity observed in the CNS of hSOD1-G93A mice at the 
endstage. [Fig. 2]. 
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Fig. 2: Evaluation of PPARs activity in the peripheral organs of hSOD1-G93A mice at the different 
stages of the pathology. The liver, the kidney and the lung of female PPRE-Luc +/- mice transgenic 
or non-trangenic for the mutant (G93A) human SOD1 were harvested at the critical stages of the 
pathology,i.e. 30, 75, 100 days (d=days), end stage (ES). Luciferase activity was normalized to the 
total protein content. The data are expressed as RLU (Relative Luminescence Unit)/µg of total 
proteins ± SEM. The data were analyzed using GraphPad Software (PRISM) (San Diego, CA). Two-
way analysis of variance (ANOVA) followed by Bonferroni Post Test was used to compare the 
means of the different stages in the transgenic and non transgenic groups. *=p<0,05 , **=p<0,01 , 
***=p<0,001.  
 
The increase in PPAR activity which is detectable only in the CNS of hSOD1-
G93A mice was a very interesting data that we decided to further investigate.  
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Influence of starvation on PPAR transcriptional activity 
PPARs are known to be widely involved in the regulation of multiple metabolic 
processes. Therefore, we decided to verify whether the starvation that the hSOD1-
G93A mice experience in the last period of their life, due to dysphagia and 
complete paralysis which prevents them from reaching for food and water, could 
influence PPARs activity The effect of starvation was analysed on selected CNS 
areas (spinal cord and cerebellum) and peripheral organs (liver and kidney) of 
PPRE-Luc +/- mice.  
PPRE-Luc female mice were divided into two groups: one group was fed ad libitum 
(ad libitum, al) while the other group was deprived of food and water for 48 h 
(starvation, s). The animals were sacrificed and the spinal cord, the cerebellum, the 
liver and the kidney were collected and immediately stored at -80°C for subsequent 
luciferase enzymatic assay.  
The results show that the luciferase activity in the spinal cord and cerebellum is 
constant between the two experimental groups [Fig. 3]. 
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Fig. 3: Evaluation of PPARs activity in the spinal cord and cerebellum of PPRE-Luc +/- female 
mice after starvation. Female PPRE-Luc +/- mice were fed ad libitum (al) or starved (s) for 48 h. 
Luciferase activity was normalized on the total protein content. The data are expressed as RLU 
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(Relative Luminescence Unit)/µg of total proteins ± SEM. The data were analyzed using GraphPad 
Software (PRISM) (San Diego, CA). T test was used to compare the means of the different stages in 
the transgenic and non transgenic groups. No statistical significance resulted.  
 
In the liver of starved animals, luciferase activity decreases slightly compared to 
controls, while no significant variability was detected in the kidneys [Fig. 4].  
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Fig. 4: Evaluation of PPARs activity in the liver and kidneys of PPRE-Luc +/- female mice after 
starvation. Female PPRE-Luc +/- mice were fed ad libitum (al) or starved (s) for 48 h. The luciferase 
activity was normalized on the total protein content. The data are expressed as RLU (Relative 
Luminescence Unit)/µg of total proteins ± SEM. The data were analyzed using GraphPad Software 
(PRISM) (San Diego, CA). T test was used to compare the means of the different stages in the 
transgenic and non transgenic groups. *=p<0,05.  
 
The results obtained led us to conclude that the starvation does not influence PPAR 
activity neither in the peripheral organs of PPRE-Luc +/- mice nor in the CNS areas 
analysed, particularly the spinal cord which is the tissue primary compromised in 
ALS. On these bases, we concluded that the increase in PPAR activity detected in 
the PPRE-Luc+/-;hSOD1-G93A female mice was not dependent on nutritional 
defects.  
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Quantitative assay for PPARs DNA binding 
PPARs activation implies their translocation into the nucleus where they bind to the 
responsive elements in the promoter of target genes and regulate gene transcription. 
To evaluate if the nuclear translocation of PPARα, PPARβ/δ and PPARγ is 
modulated during the progression of the disease and if an increased nuclear 
translocation could be responsible for the increase in PPARs transcriptional activity 
at the end stage of the disease, we decided to quantify the amount of PPARα, 
PPARβ/δ and PPARγ in the nuclear fraction of spinal cord homogenates from 
hSOD1-G93A mice and non transgenic littermates at the different stages of the 
pathology, using an ELISA-based Transcription Factor assay specific for each 
isoform of PPARs. Female hSOD1-G93A and non transgenic littermates were 
sacrificed at 30, 75, 100 days or at the end stage and the spinal cords were 
collected.   
We found that the presence of PPARα in the nucleus undergoes a progressive non-
significant decrease in the spinal cord of hSOD1-G93A mice during the course of 
the disease and does not mimic the increase at the end stage seen with the luciferase 
assay [Fig. 5].  
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Fig. 5: Evaluation of the nuclear presence of PPARα in the spinal cord of hSOD1-G93A and non 
transgenic mice. Spinal cords of female PPRE-Luc +/- mice transgenic or non-transgenic for the 
mutant (G93A) human SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 
days (d=days), end stage (ES). The nuclear fraction was utilized for an ELISA-based assay. The data 
were expressed as optical density (O.D.)/mg of total proteins ± SEM. The data were analyzed using 
GraphPad Software (PRISM) (San Diego, CA). Two-way analysis of variance (ANOVA) followed 
by Bonferroni Post Test was used to compare the means of the different stages in the transgenic and 
non transgenic groups. *=p<0,05 , **=p<0,01 , ***=p<0,001.  
 
The nuclear presence of PPARβ/δ decreases at the onset of symptoms, i.e. 100 days 
of age, and then increases but not significantly at the end stage [Fig. 6].  
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Fig. 6: Evaluation of the nuclear presence of PPARβ/δ in the spinal cord of hSOD1-G93A and non 
transgenic mice. The spinal cords of female PPRE-Luc +/- mice transgenic or non transgenic for the 
mutant (G93A) human SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 
days (d=days), end stage (ES). The nuclear fraction was utilized for an ELISA-based assay. The data 
were expressed as optical density (O.D.)/mg of total proteins ± SEM. The data were analyzed using 
GraphPad Software (PRISM) (San Diego, CA). Two-way analysis of variance (ANOVA) followed 
by Bonferroni Post Test was used to compare the means of the different stages in the transgenic and 
non transgenic groups. The statistical analysis does not show any significance.  
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The assay on the nuclear presence of PPARγ shows a decrease until 100 days of age 
and then a non significant increase at the end stage [Fig. 7].  
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Fig. 7: Evaluation of the nuclear presence of PPARγ in the spinal cord of hSOD1-G93A and non 
transgenic mice. The spinal cords of female PPRE-Luc +/- mice transgenic or non transgenic for the 
mutant (G93A) human SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 
days (d=days), end stage (ES). The nuclear fraction was utilized for an ELISA-based assay. The data 
were expressed as optical density (O.D.)/mg of total proteins ± SEM. The data were analyzed using 
GraphPad Software (PRISM) (San Diego, CA). Two-way analysis of variance (ANOVA) followed 
by Bonferroni Post Test was used to compare the means of the different stages in the transgenic and 
non transgenic groups. The statistical analysis does not show any significance.  
 
In summary, these data reveal that the worsening of the pathology does not cause an 
increased PPAR translocation into the nucleus. These assays have been performed 
on lysates from the entire spinal cord and, therefore, they do not provide any 
information on the different neural cell types. We postulated that the increase of 
PPARs activity at the end stage of the pathology could be due to an enhanced 
presence of the PPARs only in selected cell types. Furthermore ligand-dependent 
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effects derived from the interaction of PPARs with cofactors and regulatory 
molecules cannot be excluded.  
 
Analysis of the subcellular localization of PPARα, PPARβ/δ and 
PPARγ in motor neurons, astrocytes and microglia in the spinal 
cord of hSOD1-G93A mice 
To study extensively the expression and subcellular localization of the isoforms of 
PPARs in the different cell types of the spinal cord, we decided to perform 
immunohistochemical analyses on lumbar sections of spinal cords of hSOD1-G93A 
mice at different stages of the pathology.  
 
Motor neurons 
The cell type primarily involved in ALS is represented by motor neurons and, thus, 
we initially focused on these cells. Sections were double-stained with SMI32, an 
antibody specific for the non-phosphorylated neurofilaments, and antibodies 
directed against the isoform of PPAR to be analysed. The cell nuclei were stained 
with Hoechst 33342, a fluorescent dye that binds to the DNA.  
The results obtained show that PPARα is localized predominantly in the nucleus or 
equally distributed between the nucleus and the cytoplasm in motor neurons [Fig. 
8].  
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Fig. 8 PPARα shows a cytoplasmic and nuclear distribution in motor neurons. Spinal cord sections 
of female hSOD1-G93A mice at 30 days, 100 days and end stage were stained with an anti-PPARα 
antibody(red) and SMI32 antibody (green). Nuclei are stained with Hoechst 33342 (blue).  
 
PPARβ/δ is localized both in the nucleus and cytoplasm of motor neurons but it is 
more abundant into the nucleus [Fig. 9].  
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Fig. 9 PPARβ/δ shows a cytoplasmic and nuclear distribution. Spinal cord sections of female 
hSOD1-G93A mice at 30 days, 100 days and end stage were stained with an anti-PPARβ/δ rabbit 
serum (red) and SMI32 antibody (green). Nuclei are stained with Hoechst 33342 (blue).  
 
PPARγ is exclusively localized in the nuclei of motor neurons [Fig. 10].  
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Fig. 10 PPARγ shows an exclusively nuclear distribution. Spinal cord sections of female hSOD1-
G93A mice at 30 days, 100 days and end stage were stained with an anti-PPARγ antibody (red) and 
SMI32 antibody (green). Nuclei are stained with Hoechst 33342 (blue). 
 
Astrocytes 
Sections were double-stained with GFAP, an antibody directed to Glial fibrillar 
acidic protein which is widely used as an astrocytic marker, and antibodies directed 
against the isoform of PPAR to be analysed. The cell nuclei were stained with 
Hoechst 33342. PPARα [Fig. 11], PPARβ/δ [Fig. 12] and PPARγ [Fig. 13] are 
localized in the nucleus of astrocytes, but PPARα is more abundantly expressed, 
while PPARβ/δ has the lowest expression. 
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Fig. 11 PPARα shows a nuclear distribution in astrocytes. Spinal cord sections of female hSOD1-
G93A mice at 30 days, 100 days and end stage were stained with an anti-PPARα antibody(red) and 
anti-GFAP antibody (green). Nuclei are stained with Hoechst 33342 (blue).  
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Fig. 12 PPARβ/δ shows a low expression and a nuclear distribution in astrocytes. Spinal cord 
sections of female hSOD1-G93A mice at 30 days, 100 days and end stage were stained with an anti-
PPARβ/δ rabbit serum (red) and anti-GFAP antibody (green). Nuclei are stained with Hoechst 33342 
(blue).  
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Fig. 13 PPARγ shows a nuclear distribution in astrocytes. Spinal cord sections of female hSOD1-
G93A mice at 30 days, 100 days and end stage were stained with an anti-PPARγ antibody (red) and 
anti-GFAP antibody (green). Nuclei are stained with Hoechst 33342 (blue). 
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Microglia 
Sections were double-stained with Tomato lectin, which recognizes microglia, and 
antibodies directed against the isoform of PPAR to be analysed. The cell nuclei 
were stained with Hoechst 33342. PPARα [Fig. 14] and PPARβ/δ [Fig. 15] were 
undetectable in microglia cells. PPARγ [Fig. 16] shows a nuclear localization. 
 
Fig. 14: PPARα is undetectable in microglia. Spinal cord sections of female hSOD1-G93A mice at 
30 days, 100 days and end stage were stained with an anti-PPARα antibody (red) and Tomato lectin 
(green). Nuclei are stained with Hoechst 33342 (blue).  
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Fig. 15: PPARβ/δ is undetectable in microglia. Spinal cord sections of female hSOD1-G93A mice at 
30 days, 100 days and end stage were stained with an anti-PPARβ/δ rabbit serum (red) and Tomato 
lectin (green). Nuclei are stained with Hoechst 33342 (blue).  
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Fig. 16 PPARγ shows a nuclear distribution in microglia. Spinal cord sections of female hSOD1-
G93A mice at 30 days, 100 days and end stage were stained with an anti-PPARγ antibody (red) and 
Tomato lectin antibody (green). Nuclei are stained with Hoechst 33342 (blue). 
 
Evaluation of cells with immunopositive nuclei for PPARs during 
the pathology 
We next decided to evaluate the number of neuronal and glial cells showing 
PPARα, PPARβ/δ or PPARγ in the nucleus during the progression of the disease in 
order to identify the specific cell type(s) in which PPAR activity is modulated. 
Images of spinal cord ventral horns from hSOD1-G93A mice stained for both 
PPARs and cell specific markers were taken and motor neurons, astrocytes and 
microglia with PPARα, PPARβ/δ or PPARγ nuclear expression were counted. 
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The results show that none of the three isoforms of PPARs increases their nuclear 
translocation in the different cell types at the end stage of the disease compared to 
the earlier ages [Fig. 17, 18, 19], confirming the results obtained with the ELISA-
based Transcription Factor Assay. 
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Fig. 17 Motor neurons with PPARα, PPARβ/δ and PPARγ predominantly localized in the nucleus 
are expressed as percentage of the total number of motor neurons considered.  
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Fig. 18: Astrocytes with PPARα, PPARβ/δ and PPARγ predominantly localized in the nucleus are 
expressed as percentage of the total number of astrocytes considered.  
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Fig. 19 Microglia with PPARα, PPARβ/δ or PPARγ predominantly localized in the nucleus are 
expressed as percentage of the total number of microglia considered.  
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In summary, the results obtained so far show a strong activation of PPAR 
transcriptional activity at the end stage of the disease. The data obtained with the 
Transcription Factor Assay on the entire spinal cord and then with the 
immunohistochemical analysis on the specific cell types show that the increase in 
PPAR transcriptional activity at the end stage of the disease is not due to an 
increased translocation into the nucleus, suggesting that ligand-dependent 
mechanisms and/or different molecules recruitment are involved.  
 
Analysis of the expression of the isoform-specific PPAR target 
genes in the spinal cord of hSOD1-G93A mice 
We next sought to identify the isoform of PPARs responsible for the increase of 
luciferase activity at the end stage of hSOD1-G93A mice by analysing the 
expression of the target genes of PPARα, PPARβ/δ and PPARγ in spinal cords of 
hSOD1-G93A mice by semi-quantitative RT-PCR. We identified a target gene for 
each isoform of PPARs, i.e. medium chain acyl-CoA dehydrogenase (MCAD) for 
PPARα (Cullingford et al., 2002) Acyl CoA synthetase long chain 6 (Acsl6) for 
PPARβ/δ (Basu-Modak et al., 1999) and lipoprotein lipase (LPL) for PPARγ 
(Victor et al., 2006). 
The RT-PCR analysis of MCAD, Acsl6 and LPL showed that MCAD [Fig. 20] and 
Acsl6 [Fig. 22] levels remain fairly constant throughout the disease while LPL 
expression slightly increases at the onset of the disease (100 days), and further 
increases at the end stage [Fig. 21]. 
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Fig. 20: RT-PCR analysis of MCAD expression in the spinal cord of hSOD1-G93A mice. The spinal 
cords of female PPRE-Luc +/- mice transgenic or non-transgenic for the mutant (G93A) human 
SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 days (d=days), end stage 
(ES). The RNA was extracted, reverse transcribed to cDNA, and used as template for RT-PCR. 
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Fig. 21: RT-PCR analysis of Acsl6 expression in the spinal cord of hSOD1-G93A mice. The spinal 
cords of female PPRE-Luc +/- mice transgenic or non-transgenic for the mutant (G93A) human 
SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 days (d=days), end stage 
(ES). The RNA was extracted, reverse transcribed to cDNA, and used as template for RT-PCR. 
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LPL
 
Fig. 22: RT-PCR analysis of LPL expression in the spinal cord of hSOD1-G93A mice. The spinal 
cords of female PPRE-Luc +/- mice transgenic or non-transgenic for the mutant (G93A) human 
SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 days (d=days), end stage 
(ES). The RNA was extracted, reverse transcribed to cDNA, and used as template for RT-PCR. 
 
These results suggested that PPARγ is the isoform involved in the increase of 
PPARs activity at the end stage of the disease. 
To confirm this observation we decided to analyse the expression of other PPARγ 
target genes and we selected genes involved in the antioxidant system, like Catalase 
(Bernardo et al.; Okuno et al., 2008) and Glutathione S-transferase alpha 2 (Gsta2) 
(Park et al., 2004a), as well as the Peroxisome Proliferator Activated Receptor γ 
Coactivator α (PGC1α), a coactivator of PPARγ which is known to be regulated by 
PPARγ itself (Hondares et al., 2006). 
The RT-PCR analysis of the expression of Cat, Gsta2 and PGC1α showed that Cat 
[Fig. 23] and PGC1α [Fig. 25] show a similar trend of reduction till the onset of the 
disease, 100 days, then the levels of PGC1α slightly increase while the Cat 
expression increases in a significant manner at the end stage of the disease. Gsta2 
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expression remains fairly constant till the end stage when it increases significantly 
[Fig. 24].  
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Fig. 23: RT-PCR analysis of Cat expression in the spinal cord of hSOD1-G93A mice. The spinal 
cords of female PPRE-Luc +/- mice transgenic or non-trangenic for the mutant (G93A) human 
SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 days (d=days), end stage 
(ES). The RNA was extracted, reverse transcribed to cDNA, and used as template for RT-PCR. 
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Fig. 24: RT-PCR analysis of Gsta2 expression in the spinal cord of hSOD1-G93A mice. The spinal 
cords of female PPRE-Luc +/- mice transgenic or non-trangenic for the mutant (G93A) human 
SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 days (d=days), end stage 
(ES). The RNA was extracted, reverse transcribed to cDNA, and used as template for RT-PCR. 
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Fig. 25: RT-PCR analysis of PGC1α expression in the spinal cord of hSOD1-G93A mice. The spinal 
cords of female PPRE-Luc +/- mice transgenic or non-trangenic for the mutant (G93A) human 
SOD1 were harvested at the critical stages of the pathology, i.e. 30, 75, 100 days (d=days), end stage 
(ES). The RNA was extracted, reverse transcribed to cDNA, and used as template for RT-PCR. 
 
These results further confirmed our hypothesis that PPARγ activation increases at 
the end stage of the disease. 
 
Quantification of the nuclear fluorescence of PPARγ 
Based on the abovementioned observations, we decided to identify the cell type 
involved in the increase in PPARγ activity observed in the hSOD1-G93A mice at 
the end stage of the disease. The nuclear staining of PPARγ in the lumbar sections 
of spinal cord of nontransgenic and hSOD1-G93A mice seemed to be much more 
intense in the nuclei of motor neurons compared to the nuclei of non-neuronal cells. 
Therefore, we decided to confirm this observation by quantifying the intensity of 
the fluorescence of the signal obtained with the immunostaining for PPARγ and 
normalizing it versus the intensity of the nuclear staining obtained with Hoechst 
33342. The reason why we used this approach is because the DNA content in the 
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nuclei of motor neurons is more diluted when compared to that of the non neuronal 
cells, due to the bigger size of motor neuronal nuclei. A normalization on Hoechst 
33342 signal would take into account the component of the larger magnitude of 
motor neuronal nuclei. The quantification of fluorescence intensity was obtained 
using the NIH software ImageJ. 
The results obtained show that the intensity of the fluorescence signal of PPARγ 
staining normalized to the intensity of Hoechst 33342 staining is much more 
elevated in the nuclei of motor neurons compared to the nuclei of non-neuronal 
cells [Fig. 26]. These results demonstrate that PPARγ is abundant in motor neurons 
and led us to hypothesize that the motor neurons are the most likely cell type to be 
involved in the increase in PPARγ activity at the end stage. 
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Fig. 26: Quantification of the intensity of PPARγ staining in the nuclei of motor neurons (MN) and 
non neuronal cells (NNC) in lumbar spinal cord sections stained for PPARγ and the nuclear dye 
Hoechst 33342 from non transgenic (NTG) and hSOD1-G93A mice.   
 
 
 
 Results 
___________________________________________________________________ 
 87
Analysis of the expression of PPARγ target genes in the NSC-34 
motor neuron cell line 
On the basis of the high amount of PPARγ identified in the nuclei of motor neurons, 
we decided to focus on this cell type and to switch to a in vitro system. Thus, we 
investigated the expression of the PPARγ target genes in the NSC-34 cells, an 
immortalized mouse motor neuron cell line. 
RT-PCR analysis of LPL, Cat and PGC1α transcripts in NSC-34 cells transiently 
transfected with an expression vector coding for hSOD1-G93A showed that the 
presence of the mutant protein significantly increases the levels of the PPARγ target 
genes taken into consideration [Fig. 27]. Gsta2 expression could not be analysed in 
this cellular model due to its low expression which renders it undetectable by RT-
PCR. 
LPL Cat PGC1α
empty vector hSOD1-G93A
0.0
0.5
1.0
1.5 *
A
dj
. V
ol
. (
In
t/m
m
2 )
empty vector hSOD1-G93A
0.0
0.5
1.0
1.5
*
A
dj
. V
ol
. (
In
t/m
m
2 )
empty vector hSOD1-G93A
0.0
0.5
1.0
1.5 **
A
dj
. V
ol
. (
In
t/m
m
2 )
A
dj
. V
ol
. (
In
t/m
m
2 )
A
dj
. V
ol
. (
In
t/m
m
2 )
A
dj
. V
ol
. (
In
t/m
m
2 )
 
Fig. 27: RT-PCR analysis of LPL, Cat and PGC1α expression in the NSC-34 cells transiently 
transfected with an expression vector encoding hSOD1-G93A or an empty vector. The RNA was 
extracted, reverse transcribed to cDNA, and used as template for RT-PCR. 
 
In summary, our results demonstrate an increase of PPARγ activity at the end stage 
of the disease that, in our hypothesis, could represent a late attempt to counteract 
the neurodegenerative process. Pharmacologically anticipating the activation of 
PPARγ could result in a delay of the onset of the pathology and, thus, ameliorate 
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the disease outcome. Our results on NSC-34 cells transiently transfected with a 
vector encoding for hSOD1-G93A clearly indicate that motor neurons are the cell 
type involved in the activation of PPARγ during the degenerative process.  
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DISCUSSION 
The vast majority of neurodegenerative disorders are adult-onset, incurable 
diseases. Understanding the pathogenetic mechanisms underlying these disorders 
and finding molecules apt to correct such processes are, therefore, among the 
hottest topics of biomedical research. The need of effective therapy is also an urgent 
social need, especially in western countries, where the incidence of these conditions 
is growing up as a consequence of the aging of the populations and the increased 
lifespan.  
Amyotrophic Lateral Sclerosis is one of the most common adult-onset 
neurodegenerative diseases characterized by progressive degeneration of upper and 
lower motor neurons leading to paralysis and death due to respiratory failure within 
3-5 years from the onset. The incidence and prevalence of ALS are 1-2 and 4-6 per 
100,000 each year, respectively, with a lifetime ALS risk of 1/600 to 1/1,000 
(Pasinelli and Brown, 2006). Only one drug, riluzole, has proved effective in 
extending the lifespan of patients with ALS, but only by 3-6 months (Bensimon et 
al., 1994; Lacomblez et al., 1996). For this reason the development of effective 
therapies for this pathology is highly invocated, but to date all attempts to develop 
novel treatments have failed. In this context, two recent reports on the 
neuroprotective activity of the PPARγ agonist Pioglitazione in ALS mice result of 
considerable interest: in these studies, two independent groups demonstrated that 
Pioglitazone, an agent which is currently used in therapy for the treatment of type II 
diabetes, is neuroprotective in a mouse model of Amyotrophic Lateral Sclerosis, the 
hSOD1-G93A transgenic mice. Pioglitazone treatment started before the 
appearance of the symptoms, improved the motor performance and reduced the 
weight loss, attenuated motor neuron death and increased the survival. In addition, 
Pioglitazone reduced microglial activation and gliosis in the spinal cord, decreasing 
the production of pro-inflammatory mediators, such as iNOS, NF-kB and COX2 
(Kiaei et al., 2005; Schutz et al., 2005).While the activity of the PPARs has been 
extensively characterized in peripheral organs, due to their well-known involvement 
in different metabolic pathways, the functions of the different isoforms in the 
central nervous system have been investigated only in the last few years (Bright et 
al., 2008; Heneka and Landreth, 2007). Nevertheless, the beneficial properties of 
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the PPARs towards the diseases of the CNS has recently gained more and more 
consideration based on the anti-inflammatory and neuroprotective activities recently 
demonstrated in a variety of animal models of neuroprotective disease, like 
Multiple Sclerosis, Parkinson’s disease, Alzheimer’s disease and Amyotrophic 
Lateral Sclerosis (Heneka et al., 2005; Kiaei et al., 2005; Natarajan and Bright, 
2002; Niino et al., 2001; Schutz et al., 2005; Shimazu et al., 2005; Yan et al., 2003; 
Zhao et al., 2005).  
On this ground, we decided to investigate the transcriptional activity of PPARs in 
the the central nervous system of the hSOD1-G93A mouse line, a well-
characterized animal model of Amyotrophic Lateral Sclerosis, with the aim of 
identifying the stage of the disease at which the activity of PPARs becomes relevant 
to the pathology. To this end, we took advantage of the transgenic mouse PPRE-
Luc, available in the laboratory, in which the reporter gene luciferase is expressed 
under the control of a promoter responsive to PPARs (Ciana et al., 2007). Thus, we 
crossed the PPRE-Luc mice with the hSOD1-G93A animals to obtain mice that are 
heterozygous for the PPRE-Luc transgene and heterozygous or null for the hSOD1-
G93A transgene. These mice represent a invaluable tool to investigate the 
transcriptional activity of PPARs during the progression of the disease, because 
luciferase activity is taken as a surrogate of PPAR activity and can be more easily 
measured. The analysis of the enzymatic activity of luciferase in the spinal cord and 
the brain areas of PPRE-Luc;hSOD1-G93A mice shows an abrupt increase of 
PPAR activity at the end stage of the disease in the spinal cord, which is the organ 
principally involved in the pathology, and in all the brain areas analysed. We 
demonstrated that this phenomenon clearly depends on the pathology because it is 
not shared by the peripheral organs (e.g. kidney and liver). Furthermore, it is not 
dependent on the metabolic modifications induced from the starvation that the 
animals experience during the last days of their life when they are almost 
completely paralysed and, thus, unable to reach food and water. We suggest that the 
increase in PPAR activity at the end stage of the disease could represent a 
compensatory mechanism aimed at counteracting the intense neurodegenerative 
process which takes place at this time. We subsequently decided to further 
investigate this mechanism by identifying the isoform(s) responsible for the 
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increase of PPARs activity at the last stage of the disease and the cell type(s) 
involved. We first analysed the nuclear translocation of PPARα, PPARβ/δ and 
PPARγ in the spinal cord of hSOD1-G93A mice with an ELISA-based 
Transcription Factor Assay. The results obtained from these experiments showed 
that the overall nuclear presence of the different isoforms of PPARs does not 
change during the course of the disease. In order to obtain a cell specific 
information about the distribution of PPARs in the spinal cord, we next analysed 
the localization of PPARα, PPARβ/δ and PPARγ by immunohistochemistry on 
sections from the lumbar spinal cord of hSOD1-G93A mice at the different stages 
of the pathology using primary antibodies for the specific isoforms of PPARs and 
cell specific markers. 
Our stainings revealed that all the three isoforms of PPARs are expressed in spinal 
cord motor neurons; PPARα and PPARβ/δ are localized prevalently into the 
nucleus but show also a cytoplasmic staining, while PPARγ is exclusively nuclear. 
All the three isoforms are present also in astrocytes where they are exclusively 
nuclear and, in keeping with data published by other groups, PPARα is the most 
abundant isoform (Heneka and Landreth, 2007). Only PPARγ was detectable in 
microglia, and was localized into the nucleus. Accordingly to the literature 
microglia should express also PPARα and PPARβ/δ but PPARγ is the dominant 
isoform (Cullingford et al., 1998).  
Immunohistochemical analysis confirms that the increase in PPAR activity at the 
end stage of the disease is not dependent on the increase in the nuclear presence of 
the receptors in the different cell types of the spinal cord, suggesting that it possibly 
derives from ligand-dependent effects and/or the differential recruitment of co-
regulators. To identify the specific isoform whose activity is important during the 
pathology we analysed the expression of isoform-specific target genes, i.e. MCAD 
for PPARα (Cullingford et al., 2002), Acsl6 for PPARβ/δ (Basu-Modak et al., 
1999) and LPL for PPARγ (Victor et al., 2006). Only the expression of LPL 
abruptly increases at the end stage of the disease strongly suggesting that the 
increase in luciferase activity detected at the later stage of ALS is due to the 
activation of PPARγ. To confirm this result we analysed other PPARγ target genes, 
i.e. Catalase (Okuno et al., 2008), Glutathione S-tranferase alpha-2 (Park et al., 
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2004a) and Peroxisome Proliferator Activated Receptor gamma coactivator 1-alpha 
(Hondares et al., 2006). The RT-PCR analysis of the expression of Cat, Gsta2 and 
PGC1α showed that Cat and PGC1α show a similar trend of reduction till the onset 
of the disease, 100 days, then the levels of PGC1α slightly increase while the Cat 
expression increases in a significant manner. Gsta2 expression remains fairly 
constant till the end stage when it increases significantly. LPL, the first PPARγ 
target gene analysed in our work, is a lipase which transfers lipids to tissues by the 
hydrolysis of triglycerides in chylomicrons and VLDL particles (Davies, 1994). Its 
function in the brain has not been yet fully characterized but it was demonstrated 
that it transports membrane components such as lipids, cholesterol and vitamin E to 
neurons (Ben-Zeev et al., 1990; Nunez et al., 1995). Furthermore, LPL stimulates 
the endocytosis of lipids in neuronal cells (Paradis et al., 2003). Thus, it is 
reasonable to hypothesize that the increase in LPL expression at the end stage of the 
disease could lead to enchanced endocytosis of lipoproteins limiting the 
propagation of lipid peroxidation in the highly oxidative environment that is typical 
of ALS and possibly toxic for motor neurons (Keller et al., 1999). Furthermore, in 
keeping with our results, another group demonstrated an increase in LPL levels in 
the context of a wide analysis of differentially expressed genes in the spinal cord of 
hSOD1-G93A mice at the onset of the pathology (Chen et al., 2010). Catalase is an 
anti-oxidant enzyme which catalyzes the decomposition of hydrogen peroxide to 
water and oxygen while PGC1α is a transcriptional co-activator of PPARγ which 
has also been demonstrated to be transcriptionally regulated by PPARγ itself 
(Hondares et al., 2006). PGC1α has been reported to play a protective role on 
mitochondrial biogenesis. Interestingly, recent data showed that the levels of genes 
controlling cellular bioenergetics, expressed in response to PGC1α activation, are 
under-expressed in PD patients. Furthermore, activation of PGC1α was described to 
block dopaminergic neuronal loss in animal models of PD (Zheng et al., 2010). It is 
not surprising that catalase and PGC1α tend to decrease during the progression of 
the disease when the anti-oxidant system and the mitochondrial function become 
progressively impaired. Conversely, their increase at the end stage of the disease is 
probably dependent on PPARγ activation in an attempt to provide a late protective 
reaction. Glutathione S-transferase alpha-2 belongs to the family of Glutathione S-
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transferases which detoxify a wide variety of compounds, such as xenobiotics or 
endogenous compounds like peroxidised lipids, by conjugating reduced glutathione 
to the electrophilic center of the substrate (Berhane et al., 1994). Its PPARγ-
dependent activation at the last stage of the disease could represent a protective 
action directed to scavenge the peroxidised lipid that are present in the degenerated 
nervous tissue.  
Several lines of evidence indicate that the activity of PPARγ is involved in a wide 
variety of biological processes. It follows that the pharmacological activation of 
PPARγ in the context of Amyotrophic Lateral Sclerosis could represent a sort of 
“multi-targeted” approach that could address different mechanisms that are de-
regulated in the neurodegenerative process. In their studies, Kiaei and Schutz (Kiaei 
et al., 2005; Schutz et al., 2005) slowed the progression of the pathology by 
reducing neuronal cell death and ameliorating the symptoms with a chronic 
treatment with Pioglitazone started before the onset of the pathology. In view of the 
data obtained in the course of this thesis, we postulate that the protective effect of 
Pioglitazone could be due to an anticipation of the protective reaction that we 
observe at the end stage of the pathology. Pharmacologically bursting this multi-
faceted protective reaction could help counteracting the degenerative process before 
overt neuronal death takes place. Furthermore, it could also contribute to maintain 
in an active status the compensatory mechanisms of the CNS that have possibly 
been triggered in response to the early neurodegenerative events, but that fail soon 
when neuronal dysfunction reaches a critical threshold.  
On these bases we decided to further investigate the mechanisms of PPARγ 
activation at the end stage of the disease by identifying the cell type involved. 
The analysis of the fluorescence intensity into the cellular nuclei of lumbar spinal 
cord sections stained for PPARγ demonstrated that the intensity of the receptor 
signal is greater in motor neurons than in non- neuronal cells. This result is in line 
with the demonstration provided by Sarruf and colleagues that the levels of PPARγ 
are markedly reduced in both whole brain and hypothalamus of neuron-specific 
PPARγ knock out mice, thus indicating that neurons are the predominant source of 
PPARγ in the central nervous system (Sarruf et al., 2009). This data led us to 
hypothesize that motor neurons could be the most likely cell type involved in the 
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activation of PPARγ at the end stage of the disease in vivo. Thus, we decided to 
analyse the expression of the PPARγ target genes previously analysed in the spinal 
cords of hSOD1-G93A mice in an immortalized motor neuronal cell line, the NSC-
34 cells. NSC-34 is a hybrid cell line produced by fusion of motor neuron enriched, 
embryonic mouse spinal cord cells with mouse neuroblastoma (Cashman et al., 
1992) and represents the best available model for the studies on motor neuron 
biology. 
The expression of LPL, Cat and PGC1α in NSC-34 cells transiently transfected 
with the hSOD1-G93A-encoding expression vector is significantly increased as 
compared to the NSC-34 cells transfected with the empty vector. These data clearly 
confirm the involvement of motor neurons in PPARγ activation at the last stage of 
the disease; future studies will be aimed to further elucidate the molecular 
mechanisms of PPARγ protective activity on motor neurons in ALS. 
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